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Abstract	  Chronic	  Kidney	  Disease	  (CKD)	  is	  associated	  with	  much	  morbidity	  and	  mortality	  in	  the	  general	  population.	  	  It	  not	  only	  is	  a	  precursor	  for	  End-­‐stage	  renal	  disease	  (ESRD),	  but	  also	  serves	  as	  a	  significant	  risk	  factor	  for	  cardiovascular	  disease.	  	  The	  care	  of	  patients	  with	  CKD	  is	  complex	  and	  often	  involves	  blood	  pressure	  lowering,	  renin-­‐angiotensin	  system	  interruption,	  lipid	  lowering,	  anemia	  management,	  and	  control	  of	  mineral	  metabolism.	  	  Currently,	  the	  literature	  lacks	  evidence	  and	  consensus	  regarding	  how	  best	  to	  deliver	  care	  to	  this	  patient	  population.	  	  In	  particular,	  the	  degree	  of	  specialist	  involvement,	  care	  consistency,	  nursing	  expertise	  and	  multidisciplinary	  team	  involvement	  may	  all	  influence	  achievement	  of	  treatment	  targets	  and	  ultimately	  patient	  outcomes.	  	  	  	  CANPREVENT	  was	  a	  randomized	  controlled	  multicentre	  trial	  with	  500	  subjects	  comparing	  usual	  care	  by	  a	  primary	  physician	  to	  a	  model	  of	  CKD	  care	  involving	  a	  nurse	  as	  a	  primary	  caregiver	  supported	  by	  a	  nephrologist.	  	  This	  model	  proposes	  the	  delivery	  of	  a	  chronic	  disease	  management	  clinic	  with	  multiple	  risk	  factor	  intervention	  for	  people	  with	  moderate	  chronic	  kidney	  disease.	  	  By	  further	  analyzing	  data	  from	  this	  trial	  across	  the	  five	  trial	  sites,	  we	  examined	  whether	  differences	  in	  nursing	  educational	  background,	  and	  staffing	  consistency	  during	  the	  trial,	  all	  of	  which	  differed	  by	  site,	  were	  associated	  with	  achievement	  of	  treatment	  targets	  and	  surrogate	  outcomes.	  	  The	  hope	  was	  that	  the	  results	  would	  help	  direct	  future	  care	  and	  research	  into	  care	  delivery	  for	  chronic	  disease.	  	  In	  this	  analysis,	  no	  major	  differences	  in	  the	  clinical	  practice	  patterns	  were	  detected	  amongst	  the	  interventional	  sites.	  	  Overall,	  none	  of	  the	  interventional	  sites	  had	  consistently	  superior	  adherence	  rates	  for	  clinical	  interventions.	  	  However,	  the	  small	  number	  of	  sites	  and	  the	  low	  numbers	  of	  eligible	  participants	  at	  each	  site,	  reduced	  the	  power	  of	  the	  analysis.	  	  Based	  on	  these	  results,	  no	  clear	  definite	  association	  can	  be	  drawn	  between	  interventional	  sites,	  nursing	  expertise,	  continuity	  of	  care	  and	  practice	  pattern.	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Introduction	  	  Patients	  with	  multiple	  chronic	  conditions	  consume	  a	  significant	  portion	  of	  health	  care	  resources.(1)	  End	  stage	  renal	  disease	  (ESRD)	  is	  a	  leading	  example	  of	  such	  a	  condition	  given	  that	  its	  incidence	  continues	  to	  grow	  rapidly	  in	  North	  America.	  	  In	  particular,	  the	  incidence	  of	  ESRD	  grew	  steadily	  at	  over	  7%	  per	  annum	  in	  Canada	  over	  the	  past	  decade.	  	  Moreover,	  in	  2010,	  there	  was	  a	  13%	  increase	  of	  newly	  diagnosed	  patients	  with	  ESRD	  when	  compared	  to	  2001.	  	  It	  follows	  that	  the	  prevalence	  rates	  of	  patients	  with	  ESRD	  are	  also	  increasing.	  	  For	  instance,	  in	  2010,	  there	  were	  23,188	  individuals	  receiving	  dialysis	  in	  Canada,	  representing	  a	  189%	  increase	  from	  1991.	  (2)	  	  Identifying	  individuals	  at	  risk	  of	  developing	  ESRD,	  as	  well	  as	  implementing	  cost-­‐effective	  management	  strategies	  for	  these	  individuals	  should	  be	  a	  priority	  in	  controlling	  this	  chronic	  condition.	  	  	  Hence,	  a	  study	  of	  care	  processes	  to	  manage	  Chronic	  Kidney	  Disease	  (CKD)	  is	  vitally	  important.	  	  The	  goal	  of	  this	  study	  was	  to	  examine	  the	  role	  of	  relational	  continuity,	  nursing	  education	  and	  expertise,	  and	  the	  degree	  of	  involvement	  of	  nephrologists	  in	  the	  care	  of	  patients	  with	  CKD	  in	  achieving	  optimal	  care	  processes	  and	  outcomes.	  	  The	  majority	  of	  ESRD	  cases	  result	  from	  progressive	  Chronic	  Kidney	  Disease	  (CKD).(3)	  This	  is	  due	  to	  the	  fact	  that	  in	  CKD,	  extra	  stress	  is	  placed	  on	  the	  remaining	  healthy	  nephrons,	  thereby	  shortening	  their	  lifespan.	  	  As	  well,	  the	  state	  of	  CKD	  often	  exacerbates	  certain	  risk	  factors	  such	  as	  hypertension	  and	  hyperglycemia,	  which	  will	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further	  promote	  progressive	  renal	  damage	  and	  hence	  ESRD.	  	  Consequently,	  preventing	  the	  development	  of	  CKD	  will	  also	  decrease	  the	  incidence	  of	  ESRD.	  	  	  	  Furthermore,	  individuals	  with	  CKD	  are	  also	  at	  risk	  of	  developing	  cardiovascular	  disease.	  	  	  This	  is	  because	  CKD	  shares	  many	  similar	  risk	  factors	  as	  cardiovascular	  disease,	  and	  these	  include	  hypertension,	  dyslipidemia,	  smoking,	  and	  diabetes.	  	  It	  follows	  that	  CKD	  and	  cardiovascular	  disease	  often	  develop	  and	  progress	  concurrently	  due	  to	  similar	  pathogenetic	  pathways.	  	  These	  pathways	  include	  oxidative	  stress,	  chronic	  inflammation,	  vascular	  (intima	  and	  media)	  calcifications,	  and	  atherosclerotic	  plaque	  formation.	  	  Therefore,	  patients	  with	  CKD	  often	  have	  comorbid	  cardiovascular	  disease,	  which	  leads	  to	  even	  greater	  rates	  of	  morbidity	  and	  mortality.	  	  	  	  	  	  Nevertheless,	  some	  of	  the	  risk	  factors	  attributed	  to	  both	  CKD	  and	  cardiovascular	  disease	  have	  been	  shown	  to	  be	  modifiable	  in	  clinical	  trials.	  	  In	  particular,	  antagonism	  of	  the	  renin	  angiotensin	  system,	  treatment	  of	  hypertension	  and	  proper	  treatment	  of	  diabetes	  have	  all	  been	  shown	  to	  have	  both	  cardiovascular	  benefit	  as	  well	  as	  slowing	  the	  progress	  of	  CKD.	  	  Cholesterol-­‐lowering	  strategies	  have	  been	  shown	  to	  decrease	  rates	  of	  cardiovascular-­‐related	  complications.	  Furthermore,	  there	  are	  targeted	  risk-­‐reducing	  strategies	  unique	  to	  CKD	  such	  as	  anemia,	  mineral	  metabolism,	  and	  metabolic	  acidosis	  management	  which	  have	  also	  been	  shown	  to	  confer	  varying	  degrees	  of	  clinical	  benefit.	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Modifiable	  risk	  factors	  for	  CVD	  and	  CKD	  Numerous	  large,	  randomized	  control	  trials	  have	  shown	  that	  Angiotensin-­‐converting	  enzyme	  inhibitors	  (ACEIs)	  are	  superior	  to	  non-­‐ACEI	  in	  reducing	  progression	  of	  renal	  disease,	  reducing	  ischemic	  heart	  disease	  and	  congestive	  heart	  failure	  event	  rates,	  and	  reducing	  mortality.(4-­‐6)	  The	  effect	  of	  ACEI	  on	  cardiovascular	  disease	  appears	  to	  be	  similar	  in	  patients	  with	  and	  without	  mild	  to	  moderate	  renal	  failure.	  	  RAS	  antagonism	  with	  angiotensin	  receptor	  blocker	  (ARB)	  also	  reduced	  proteinuria	  and	  lengthened	  the	  time	  to	  dialysis	  or	  doubling	  of	  serum	  creatinine	  when	  compared	  to	  placebo	  in	  type	  2	  diabetics.(7-­‐9)	  One	  ARB	  trial	  has	  shown	  a	  clinically	  and	  statistically	  significant	  reduction	  in	  mortality	  compared	  to	  the	  beta-­‐blocker	  atenolol	  in	  patients	  with	  hypertension	  and	  left	  ventricular	  hypertrophy.(10)	  	  ARBs	  have	  not	  been	  proven	  better	  than	  ACEIs	  in	  trials	  in	  CHF	  or	  post	  MI.	  	  The	  confidence	  intervals	  in	  general	  have	  excluded	  significant	  superiority	  but	  have	  included	  the	  possibility	  of	  clinically	  significant	  inferiority,	  allowing	  the	  possibility	  that	  ARBs	  may	  not	  be	  as	  cardio-­‐protective	  as	  ACEIs.(11,	  12)	  	  In	  one	  trial	  comparing	  an	  ARB	  to	  an	  ACEI	  in	  patients	  with	  established	  cardiovascular	  disease	  or	  diabetes,	  patients	  in	  each	  group	  had	  similar	  rates	  of	  the	  primary	  outcome,	  a	  composite	  of	  death	  from	  cardiovascular	  causes,	  myocardial	  infarction,	  stroke	  or	  hospitalization	  for	  heart	  failure.(13)	  The	  results	  of	  that	  trial	  also	  suggest	  that	  the	  combination	  of	  an	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ACEI	  and	  ARB	  was	  not	  superior	  to	  an	  ACEI	  alone,	  but	  may	  result	  in	  higher	  rates	  of	  adverse	  events.	  	  	  	  	  	  Poorly	  controlled	  blood	  glucose	  is	  associated	  with	  progression	  of	  diabetic	  nephropathy	  as	  well	  as	  the	  development	  of	  cardiovascular	  disease.	  	  Controlling	  diabetes	  in	  Type	  I	  and	  Type	  II	  diabetic	  patients	  has	  beneficial	  effects	  for	  prevention	  of	  microvascular	  disease,(14-­‐16)	  an	  example	  of	  which	  would	  be	  nephropathy.	  	  Hypertension	  is	  a	  long	  established	  risk	  factor	  for	  premature	  death,	  ischemic	  heart	  disease,	  congestive	  heart	  failure	  and	  left	  ventricular	  hypertrophy	  in	  the	  general	  population.	  	  In	  patients	  with	  CKD,	  hypertension	  can	  lead	  to	  progression	  of	  renal	  disease,	  ischemic	  heart	  disease,	  congestive	  heart	  failure,	  left	  ventricular	  hypertrophy	  and	  death.	  	  The	  established	  national	  guidelines	  at	  the	  time	  of	  the	  study	  recommended	  a	  blood	  pressure	  target	  of	  below	  130/80	  mmHg	  in	  patients	  with	  CKD.(17-­‐20)	  	  However,	  the	  more	  recent	  CHEP	  (Canadian	  Hypertension	  Education	  Program)	  guidelines	  recommend	  a	  blood	  pressure	  target	  of	  below	  140/90	  mmHg	  in	  nondiabetic	  patients	  with	  or	  without	  CKD.(21)	  	  Elevated	  LDL	  (Low-­‐Density	  Lipoprotein)	  cholesterol	  is	  a	  well-­‐established	  risk	  factor	  for	  atherosclerosis,	  cardiovascular	  disease	  and	  death	  in	  certain	  at-­‐risk	  populations.(22-­‐24)	  Therefore,	  the	  national	  guidelines	  at	  the	  time	  of	  the	  study	  recommended	  that	  cholesterol	  reduction	  with	  HMG-­‐CoA	  (5-­‐hydroxy-­‐3-­‐
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methylglutaryl-­‐coenzyme	  A)	  reductase	  inhibitor	  (statin)	  in	  all	  patients	  with	  diabetes,	  established	  atherosclerotic	  disease,	  or	  persistent	  LDL	  above	  2.5	  mmol/L	  should	  be	  instituted.	  	  The	  recently	  published	  SHARP	  (Study	  of	  Heart	  and	  Renal	  Protection)	  demonstrated	  that	  reduction	  of	  LDL	  cholesterol	  in	  a	  wide	  range	  of	  patients	  with	  advanced	  CKD	  with	  simvastatin	  and	  ezetimibe	  reduced	  the	  incidence	  of	  major	  atherosclerotic	  events.(25)	  	  
Modifiable	  risk	  factors	  relating	  to	  CVD	  	  It	  is	  well	  established	  that	  antiplatelet	  therapy	  is	  effective	  for	  prevention	  of	  cardiovascular	  events	  in	  patients	  with	  known	  atherosclerotic	  disease,	  such	  as	  peripheral	  vascular	  disease,	  ischemic	  stroke,	  ischemic	  heart	  disease,	  and	  post	  myocardial	  infarction	  as	  well	  as	  in	  diabetic	  patients.	  	  An	  observational	  study	  of	  outcomes	  following	  myocardial	  infarction	  in	  patients	  with	  CKD	  showed	  that	  ASA	  use	  is	  associated	  with	  improved	  post-­‐myocardial	  infarction	  survival	  across	  a	  broad	  spectrum	  of	  renal	  function.(26)	  	  Antiplatelet	  use	  in	  diabetics	  was	  consistent	  with	  the	  guidelines	  at	  the	  time	  of	  the	  study,	  although	  is	  use	  being	  questioned	  more	  recently	  in	  diabetics	  without	  established	  vascular	  disease.	  	  
Modifiable	  risk	  factors	  relating	  to	  CKD	  Several	  cohort	  studies	  have	  demonstrated	  an	  association	  between	  anemia	  and	  mortality	  and	  morbidity	  in	  patients	  with	  renal	  disease.	  	  Anemia	  is	  a	  risk	  factor	  for	  LVH,	  CHF,	  hospitalization,	  and	  death	  in	  patients	  on	  dialysis.(27,	  28)	  	  The	  presence	  of	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anemia	  in	  patients	  with	  CKD	  also	  predicts	  development	  of	  left	  ventricular	  hypertrophy,	  which	  has	  been	  associated	  with	  cardiovascular	  events	  and	  death	  in	  the	  general	  population,	  dialysis	  and	  kidney	  transplant	  recipients.(29)	  However,	  as	  of	  now,	  no	  intervention	  study	  has	  demonstrated	  a	  clear	  survival	  benefit	  of	  anemia	  treatment	  with	  erythropoietin	  in	  patients	  on	  dialysis,	  or	  with	  CKD,	  or	  in	  kidney	  transplant	  recipients.	  	  Nevertheless,	  due	  to	  the	  benefit	  of	  reducing	  blood	  transfusion	  and	  anemia-­‐related	  symptoms,	  the	  international	  nephrology	  consortium,	  KDIGO	  (Kidney	  Disease:	  Improving	  Global	  Outcomes)	  guidelines	  recommend	  using	  erythropoiesis	  stimulating	  agents	  to	  maintain	  a	  hemoglobin	  level	  between	  90	  to	  115	  g/L.(30)	  	  Abnormalities	  of	  mineral	  metabolism	  and	  secondary	  hyperparathyroidism	  occur	  	  concurrently	  with	  CKD,	  and	  have	  numerous	  physiological	  effects	  on	  renal	  function,	  cardiovascular	  function	  and	  bone	  metabolism.	  	  	  Registry	  data	  have	  demonstrated	  higher	  mortality	  rates	  in	  ESRD	  patients	  with	  abnormal	  serum	  phosphate	  and	  serum	  phosphate	  and	  calcium	  product.(31)	  Higher	  rates	  of	  cardiac	  mortality	  are	  also	  associated	  with	  elevated	  serum	  phosphate,	  phosphate	  and	  calcium	  product,	  and	  parathyroid	  hormone	  levels.(32)	  However,	  there	  is	  currently	  a	  lack	  of	  interventional	  research	  showing	  improved	  clinical	  outcome	  with	  control	  of	  serum	  phosphate	  levels	  with	  dietary	  binders.	  	  A	  recently	  published	  randomized	  control	  trial	  in	  hemodialysis	  patients	  with	  moderate-­‐to-­‐severe	  secondary	  hyperparathyroidism	  comparing	  cinacalcet	  (a	  calcimimetic	  agent	  that	  acts	  by	  allosteric	  activation	  of	  the	  calcium-­‐
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sensing	  receptor	  on	  parathyroid	  tissue)	  to	  placebo,	  showed	  no	  statistical	  difference	  in	  the	  primary	  composite	  end	  point	  of	  time	  until	  death,	  myocardial	  infarction,	  hospitalization	  for	  unstable	  angina,	  heart	  failure,	  or	  a	  peripheral	  vascular	  event.(33)	  Although	  patients	  in	  the	  cinacalcet	  arm	  had	  a	  50%	  risk	  reduction	  in	  requiring	  surgery	  to	  remove	  part	  of	  their	  parathyroid	  glands	  in	  order	  to	  control	  the	  hyperparathyroidism.	  	  Another	  modifiable	  risk	  factor	  in	  patients	  in	  CKD	  is	  metabolic	  acidosis.	  	  	  It	  is	  associated	  with	  multiple	  adverse	  outcomes	  including	  malnutrition	  and	  abnormalities	  of	  bone	  mineral	  metabolism(34,	  35).	  	  Furthermore,	  metabolic	  acidosis	  may	  activate	  the	  complement	  cascade,	  in	  part	  through	  increasing	  the	  need	  for	  NH4	  excretion,	  thus	  leading	  to	  increased	  interstitial	  fibrosis	  and	  possibly	  accelerated	  renal	  function	  decline(36).	  Recently,	  a	  small	  randomized	  controlled	  trial	  showed	  that	  bicarbonate	  supplementation	  slowed	  the	  progression	  of	  renal	  disease(37).	  	  
Care	  of	  CKD	  patients	  Ideally,	  comprehensive	  care	  for	  a	  patient	  with	  CKD	  should	  therefore	  comprise	  of	  management	  of	  all	  of	  the	  above	  risk	  factors.	  	  Therefore,	  there	  is	  huge	  potential	  in	  recognizing	  and	  treating	  CKD	  patients	  at	  earlier	  stages	  (3	  and	  4)	  in	  order	  to	  prevent	  significant	  clinical	  endpoints	  and	  improve	  health	  outcomes,	  thereby	  limiting	  potential	  health	  care	  costs	  to	  society.	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Despite	  this	  rationale	  for	  early	  intervention,	  studies	  suggest	  that	  clinical	  targets	  such	  as	  blood	  pressure	  control	  and	  use	  of	  cardioprotective	  medications	  for	  treating	  patients	  with	  earlier	  stages	  of	  CKD	  are	  generally	  not	  met,	  (38,	  39).	  Care	  coordination	  and	  integration	  through	  primary	  health	  providers	  is	  often	  variable	  and	  fragmented	  where	  scheduled	  follow-­‐up	  is	  often	  insufficient	  for	  treating	  chronic	  conditions.	  	  As	  a	  result,	  patients	  with	  CKD	  may	  not	  consistently	  receive	  optimal	  care.	  	  In	  particular,	  patients	  with	  CKD	  often	  experience	  care	  gaps	  between	  recommended	  care	  and	  actual	  received	  care.	  	  They	  also	  routinely	  experience	  underutilization	  of	  therapies	  with	  proven	  efficacy(39-­‐42).	  	  Approaches	  for	  targeting	  patients	  with	  CKD	  and	  related	  comorbidities	  vary	  across	  the	  developed	  world.	  	  For	  instance,	  researchers	  in	  United	  Kingdom	  have	  proposed	  a	  program	  for	  at	  risk	  populations,	  such	  as	  people	  with	  diabetes,	  hypertension	  and/or	  cardiovascular	  disease,	  by	  seeking	  out	  cases	  of	  CKD	  early	  by	  searching	  established	  patient	  electronic	  databases(43).	  The	  identified	  patients	  would	  be	  flagged	  for	  intensified	  primary	  care	  management	  for	  their	  risk	  factors	  (such	  as	  blood	  pressure	  and	  diabetes	  control)	  for	  CKD	  progression	  and	  of	  their	  cardiovascular	  risk,	  as	  well	  as	  facilitating	  earlier	  referrals	  to	  specialists(44).	  	  In	  the	  United	  States,	  disease	  management	  strategies	  for	  CKD	  have	  been	  proposed	  and	  developed	  in	  the	  context	  of	  managed	  care.(45,	  46)	  	  For	  example,	  a	  disease	  management	  organization	  can	  institute	  a	  comprehensive	  and	  integrated	  approach	  to	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CKD	  care	  delivery	  which	  focuses	  on	  slowing	  the	  progression	  of	  CKD,	  identifying	  and	  treating	  CKD-­‐specific	  complications,	  managing	  CKD-­‐related	  comorbidities,	  and	  smoothing	  the	  transition	  to	  ESRD	  care,	  in	  an	  effort	  to	  improve	  clinical	  outcomes	  as	  well	  as	  providing	  cost	  savings(45,	  47).	  This	  approach	  of	  intervention	  at	  earlier	  stages	  of	  CKD	  has	  been	  shown	  in	  small	  observational	  studies	  to	  improve	  renal-­‐related	  outcomes	  as	  well	  as	  preventing	  complications	  from	  comorbidities(48).	  	  	  In	  Canada,	  multidisciplinary	  team-­‐based	  CKD	  care	  is	  common	  and	  has	  been	  shown	  to	  be	  clinically	  superior	  to	  standard	  nephrologist	  care	  in	  a	  multicentre	  observational	  study(49).	  Specifically,	  in	  a	  mixed	  Canadian/Italian	  cohort,	  there	  was	  a	  survival	  advantage	  for	  those	  exposed	  to	  formalized	  clinic	  care	  (consisting	  of	  a	  nurse	  educator,	  physician,	  social	  worker,	  nutritionist,	  psychologist	  and	  pharmacist)	  in	  addition	  to	  standard	  nephrologist	  follow-­‐up.	  	  However,	  this	  was	  not	  a	  randomized	  controlled	  trial	  and	  major	  differences	  between	  the	  groups	  at	  baseline	  (age,	  race,	  and	  creatinine	  clearance	  at	  the	  start	  of	  dialysis)	  could	  have	  biased	  the	  study’s	  results(49).	  	  	  	  Based	  on	  the	  current	  literature,	  an	  alternative	  method	  of	  care	  delivery	  would	  be	  beneficial	  in	  the	  complex	  management	  of	  	  CKD	  patients.	  	  
Patient	  care	  delivery	  by	  nurses	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Registered	  nurses	  involved	  in	  direct	  patient	  care	  can	  have	  varying	  levels	  of	  nursing	  education	  including	  a	  Diploma	  in	  Nursing,	  Baccalaureate	  degree	  in	  Nursing,	  and	  Master	  of	  Science	  in	  Nursing	  (or	  Master	  of	  Nursing).	  	  Level	  of	  nursing	  education	  has	  been	  shown	  to	  affect	  overall	  patient	  care.	  	  For	  instance,	  hospital	  units	  with	  a	  high	  proportion	  of	  baccalaureate-­‐prepared	  nurses	  had	  more	  positive	  reports	  of	  patient	  teaching(50),	  registered	  nurses	  with	  baccalaureate	  degrees	  perform	  higher	  skill	  functions	  than	  graduates	  of	  diploma	  programs(51),	  and	  hospital	  units	  with	  registered	  nurses	  with	  higher	  education	  are	  associated	  with	  improved	  patient	  safety(52-­‐54).	  	  	  	  Furthermore,	  care	  by	  nurses	  with	  specialty	  certification	  has	  been	  associated	  with	  improved	  quality	  of	  patient	  care(55).	  	  Specifically,	  subspecialty	  certification	  in	  perioperative	  nurses	  contributed	  to	  improved	  self	  perceptions	  of	  competence,	  	  while	  additional	  nursing	  subspecialty	  certification	  in	  the	  intensive	  care	  unit	  has	  been	  associated	  with	  increased	  perceptions	  of	  workplace	  empowerment(56).	  	  In	  other	  studies,	  additional	  nursing	  certification	  was	  found	  to	  be	  associated	  with	  decreased	  falls	  in	  a	  sample	  of	  medical	  and	  surgical	  inpatient	  units(57),	  and	  in	  various	  inpatient	  surgical	  services,	  a	  positive	  association	  was	  found	  between	  specialty	  certification	  and	  30-­‐day	  mortality	  rates(58).	  	  	  Different	  nursing	  models	  have	  also	  previously	  been	  explored	  in	  caring	  for	  patients	  with	  CKD.(59-­‐63)	  These	  include	  nurse-­‐run	  clinics,	  specialized	  nephrology	  nurses	  set	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up	  as	  a	  group	  to	  facilitate	  patient	  care(60),	  or	  involvement	  of	  a	  nurse	  practitioner	  with	  specialty	  nephrology	  training	  as	  the	  primary	  care	  provider(62).	  	  	  The	  addition	  of	  a	  nurse	  practitioner	  as	  the	  coordinator	  of	  the	  medical	  care	  team	  may	  promote	  adherence	  to	  lifestyle	  recommendations.	  	  In	  a	  randomized	  trial,	  in	  which	  over	  1000	  largely	  female	  Hispanic	  middle-­‐aged	  participants	  were	  recruited	  from	  multiple	  primary	  care	  clinics	  in	  the	  United	  States,	  and	  where	  nurse	  practitioner	  and	  physician	  care	  were	  compared,	  suggested	  that	  no	  significant	  differences	  	  in	  patients’	  health	  status	  (p=0.92)	  and	  satisfaction	  ratings	  (p=0.88),	  up	  to	  a	  follow-­‐up	  of	  two	  years.(64,	  65)	  	  This	  suggests	  that	  the	  quality	  of	  care	  delivered	  by	  nurse	  practitioners	  is	  comparable	  to	  that	  of	  physicians	  in	  a	  primary	  care	  setting	  for	  this	  particular	  patient	  population.	  	  	  Furthermore,	  in	  a	  recent	  randomized	  trial	  from	  the	  Netherlands,	  with	  just	  under	  800	  mostly	  Caucasian	  male	  participants,	  the	  addition	  of	  a	  nurse	  practitioner	  to	  standard	  nephrologist	  care	  in	  CKD	  patients	  was	  examined.	  	  The	  results	  suggested	  that	  the	  intervention	  and	  control	  groups	  had	  similar	  rates	  of	  the	  primary	  composite	  end	  point	  (myocardial	  infarction,	  stroke	  or	  cardiovascular	  death)	  or	  secondary	  end	  outcomes	  (vascular	  interventions,	  all-­‐cause	  mortality	  or	  ESRD).(66)	  Despite	  various	  approaches	  and	  models	  of	  care	  ,	  the	  optimal	  degree	  of	  nursing	  background	  preparation	  and	  further	  specialty	  training	  and	  expertise	  in	  caring	  for	  this	  patient	  population	  is	  still	  unclear	  from	  the	  current	  literature.	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Continuity	  of	  Care	  Moreover,	  as	  patients	  with	  CKD	  often	  present	  with	  an	  array	  of	  complex	  medical	  issues,	  the	  implementation	  of	  a	  structured	  clinic	  with	  good	  continuity	  of	  care	  may	  be	  important.	  	  For	  example,	  continuity	  of	  care	  can	  be	  achieved	  by	  “relational	  continuity,”	  where	  a	  sustained	  interaction	  between	  patient	  and	  provider	  over	  time	  has	  been	  associated	  with	  improvements	  in	  care	  (i.e.	  better	  recognition	  of	  problems,	  diagnostic	  accuracy,	  medication	  adherence,	  and	  reduced	  hospitalization).(67)	  	  	  	  The	  current	  literature	  supports	  the	  benefit	  of	  relational	  continuity	  across	  different	  health	  care	  domains.	  	  For	  instance,	  in	  primary	  care	  where	  relational	  continuity	  is	  regarded	  as	  a	  central	  concept,	  it	  is	  often	  accomplished	  by	  having	  a	  single	  care-­‐provider.	  	  This	  has	  been	  shown	  to	  improve	  compliance	  with	  medical	  instruction,	  patient	  satisfaction,	  among	  other	  benefits(68).	  	  With	  respect	  to	  mental	  health	  care,	  relationship	  continuity	  is	  achieved	  through	  coordination	  of	  medical	  services	  by	  a	  health	  care	  team.	  	  These	  “continuous	  treatment	  teams”	  are	  responsible	  for	  all	  of	  the	  patients’	  medical	  and	  psychosocial	  needs,	  integrating	  complex	  mental	  health	  care	  in	  a	  number	  of	  successful	  programs	  in	  the	  United	  States.(69)	  	  Varying	  degrees	  of	  relational	  continuity	  in	  care	  of	  patients	  with	  chronic	  diseases	  such	  as	  AIDS,	  diabetes,	  cardiovascular	  disease,	  rheumatologic	  conditions,	  and	  cancer	  have	  been	  described.(67)	  	  The	  emphasis	  is	  placed	  on	  delivery	  of	  services	  by	  different	  providers	  in	  a	  coherent,	  logical	  and	  timely	  fashion,	  ultimately	  resulting	  in	  reduction	  in	  hospital	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length	  of	  stay,	  reduction	  in	  costs,	  improved	  patient	  quality	  of	  life,	  increased	  patient	  satisfaction,	  and	  reduction	  in	  the	  time	  on	  carrying	  out	  paperwork.(70)	  	  	  In	  2011,	  Dr.	  John	  Knight	  demonstrated	  that	  higher	  continuity	  of	  family	  physician	  care	  	  is	  associated	  with	  reduced	  specialist	  utilization	  and	  hospitalization	  for	  ambulatory-­‐care	  sensitive	  conditions	  (i.e.	  avoidable	  admissions),	  as	  well	  as	  reduced	  costs	  associated	  with	  specialist,	  total	  physician	  and	  hospital	  utilization	  in	  a	  Canadian	  province.(71)	  	  Using	  data	  from	  cross-­‐sectional	  analyses	  of	  survey	  and	  provincial	  health	  insurance	  registry	  samples,	  this	  study	  demonstrated	  even	  stronger	  associations	  in	  the	  case	  of	  older	  patients.(71)	  	  Whether	  relational	  continuity	  can	  improve	  outcomes	  in	  CKD	  patients	  is	  still	  unclear	  in	  the	  current	  literature.	  	  	  Despite	  ample	  evidence	  for	  individual	  risk	  factor	  reduction,	  how	  best	  to	  implement	  all	  these	  clinical	  interventions	  in	  CKD	  is	  unknown.	  	  While	  other	  chronic	  diseases	  such	  as	  diabetes	  mellitus	  have	  been	  shown	  to	  benefit	  from	  multifactorial	  risk	  reducing	  strategies,(16)	  trials	  with	  similar	  clinical	  design	  and	  outcomes	  have	  not	  been	  replicated	  for	  management	  of	  CKD.	  Since	  there	  was	  clinical	  equipoise	  as	  to	  whether	  multifactorial	  risk	  reducing	  strategies	  in	  a	  managed	  care	  setting	  should	  all	  be	  applied	  to	  the	  care	  of	  patients	  with	  CKD,	  a	  clinical	  trial	  (CanPREVENT	  	  -­‐	  Canadian	  Collaborative	  Group	  for	  the	  Prevention	  of	  Renal	  and	  Cardiovascular	  Endpoints	  Trial)	  was	  conducted	  to	  test	  the	  hypothesis	  that	  a	  specialized	  clinic	  staffed	  by	  a	  trained	  nurse	  in	  collaboration	  with	  a	  nephrologist	  using	  a	  protocol	  guided	  multiple	  risk	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factor	  and	  disease	  management	  approach	  would	  have	  significant	  impact	  on	  clinical	  outcomes.	  	  This	  pilot	  study	  aimed	  to	  explore	  the	  feasibility	  of	  achieving	  	  pre-­‐defined	  clinical	  care	  goals	  by	  the	  interventional	  group,	  as	  well	  as	  examining	  the	  quality	  of	  life	  and	  economic	  implications	  associated	  with	  such	  care.	  	  The	  primary	  outcomes	  for	  the	  pilot	  study	  were	  anticipated	  for	  any	  potential	  follow-­‐up	  of	  a	  full	  trial	  included	  time	  to	  ESRD,	  marked	  decline	  in	  kidney	  function,	  myocardial	  infarction,	  stroke,	  hospitalization	  for	  congestive	  heart	  failure,	  leg	  amputation	  above	  the	  ankle	  or	  gangrene,	  or	  death	  due	  to	  any	  cause.	  	  The	  results	  of	  this	  trial	  are	  published	  and	  will	  be	  discussed	  later(72,	  73).	  	  However,	  questions	  remain	  regarding	  the	  role	  of	  relational	  continuity	  of	  care,	  nursing	  expertise,	  and	  the	  degree	  of	  involvement	  of	  nephrologists	  in	  the	  care	  of	  patients	  with	  CKD	  in	  achieving	  optimal	  care	  processes	  and	  outcomes.	  	  The	  CanPREVENT	  trial	  interventional	  sites	  had	  different	  research	  staffing	  consistency	  as	  well	  as	  nursing	  expertise.	  	  	  Furthermore,	  a	  preliminary	  scan	  of	  the	  data	  relevant	  to	  the	  interventional	  sites	  suggested	  that	  adherence	  to	  established	  clinical	  protocols	  differed	  across	  the	  five	  sites.	  	  By	  further	  analyzing	  the	  data	  from	  the	  trial	  across	  five	  different	  sites	  in	  Canada	  and	  exploring	  the	  difference	  in	  practice	  patterns	  between	  the	  sites,	  we	  hypothesized	  that	  the	  continuity	  of	  care	  provided	  by	  nursing	  staff	  and	  nursing	  educational	  preparation	  would	  affect	  the	  degree	  of	  provider	  adherence	  to	  established	  clinical	  protocols.
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Materials	  and	  Methods	  CanPREVENT	  	  (Canadian	  Collaborative	  Group	  for	  the	  Prevention	  of	  Renal	  and	  Cardiovascular	  Endpoints	  Trial)	  was	  a	  randomized,	  un-­‐blinded,	  parallel	  two	  group	  clinical	  trial	  in	  five	  urban	  centres	  in	  Canada.	  	  The	  study	  was	  conducted	  between	  2005	  and	  2008.	  	  The	  results	  of	  the	  clinical	  trial	  have	  been	  previously	  reported.(72-­‐74)	  It	  compared	  a	  novel	  integrated	  approach	  of	  nurse-­‐led	  chronic	  kidney	  disease	  clinic	  to	  the	  usual	  medical	  care.	  	  The	  interventional	  groups	  at	  each	  site	  in	  the	  CanPREVENT	  study	  were	  exposed	  to	  a	  protocol-­‐guided,	  multiple	  risk	  factor	  clinic	  based	  in	  a	  hospital	  run	  by	  a	  registered	  nurse	  and	  supported	  by	  a	  nephrologist.	  	  An	  orientation	  program	  was	  offered	  to	  the	  nurses,	  Web-­‐based	  resources	  were	  developed	  and	  regular	  teleconferences	  among	  the	  nurses	  were	  held.	  	  A	  series	  of	  medical	  protocols	  were	  developed	  regarding	  managing	  blood	  pressure;	  controlling	  lipids	  with	  diet	  and	  statins;	  disrupting	  the	  renin-­‐angiotensin	  II	  	  system	  with	  angiotensin	  converting	  enzyme	  inhibitors	  (or	  using	  angiotensin	  II	  receptor	  blockers	  if	  angiotensin	  converting	  enzyme	  inhibitors	  were	  not	  tolerated)	  for	  all	  patients;	  treating	  anemia;	  using	  acetylsalicylic	  acid	  to	  prevent	  atherothrombotic	  events	  in	  high	  risk	  patients;	  and	  controlling	  serum	  calcium,	  phosphorus	  and	  parathyroid	  hormone	  (PTH)	  levels	  with	  diet,	  phosphate	  binders,	  and	  activated	  vitamin	  D.	  	  In	  addition,	  lifestyle	  modifications	  were	  encouraged	  in	  the	  interventional	  group	  including	  weight	  management,	  glycemic	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control	  in	  diabetic	  patients,	  regular	  exercise,	  dietary	  sodium	  restriction	  and	  smoking	  cessation(74).	  	  The	  five	  research	  sites	  across	  Canada	  were	  in	  St.	  John’s,	  Newfoundland;	  Halifax,	  Nova	  Scotia;	  London,	  Ontario;	  Greenfield	  Park,	  Quebec;	  and	  Vancouver,	  British	  Columbia.	  	  A	  study	  investigator	  who	  is	  a	  nephrologist	  participated	  at	  each	  site.	  	  Each	  site	  also	  had	  at	  least	  one	  dedicated	  interventional	  clinic	  nurse	  who	  managed	  the	  interventional	  patients	  in	  the	  study.	  	  	  Each	  site	  followed	  the	  study	  protocol	  regarding	  recruitment	  and	  regular	  visits.	  	  	  	  However,	  the	  details	  of	  background	  preparation	  of,	  and	  continuity	  of	  care	  by	  the	  	  intervention	  group	  nursing	  staff	  varied	  across	  the	  sites.	  	  For	  instance,	  while	  Sites	  A	  and	  B	  (coded	  	  by	  letter	  to	  preserve	  site	  anonymity)	  had	  a	  consistent	  research	  nurse	  (registered	  nurses	  with	  diplomas	  and	  baccalaureate	  degree	  respectively)	  who	  interacted	  with	  patients	  in	  the	  interventional	  group,	  Site	  D	  had	  at	  least	  three	  different	  nurses	  in	  the	  same	  role	  at	  different	  times	  during	  the	  trial.	  	  At	  Site	  E,	  there	  were	  also	  staffing	  changes	  during	  the	  study	  as	  there	  were	  at	  least	  two	  nurses	  who	  interacted	  with	  the	  patients	  in	  the	  interventional	  group	  at	  different	  times	  during	  the	  study.	  	  On	  the	  other	  hand,	  Site	  C	  had	  a	  dedicated	  nephrology	  clinical	  nurse	  specialist	  with	  a	  master’s	  degree	  who	  interacted	  with	  the	  intervention	  patients	  from	  the	  start	  to	  the	  end	  of	  the	  study.	  	  This	  will	  be	  described	  in	  more	  detail	  in	  the	  Study	  Design	  section.	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  The	  inconsistency	  with	  respect	  to	  nursing	  staff	  could	  have	  impacted	  overall	  patient	  care	  and	  relational	  continuity	  of	  care	  across	  the	  five	  sites.	  	  We	  hypothesized	  that	  the	  addition	  of	  a	  specialized	  nurse	  with	  nephrology	  expertise	  as	  well	  as	  a	  consistent	  and	  continuous	  nursing	  staff	  (i.e.	  Site	  C)	  would	  translate	  into	  improved	  adherence	  of	  care	  providers	  to	  the	  defined	  medical	  protocols.	  	  	  
Study	  Design	  Data	  from	  the	  CanPREVENT	  study	  database	  were	  used	  for	  the	  purposes	  of	  this	  study;	  	  CanPREVENT	  was	  a	  randomized,	  unblinded,	  parallel	  two-­‐group	  clinical	  trial	  conducted	  in	  five	  urban	  centres	  in	  Canada.	  	  This	  present	  study	  is	  a	  prospective	  cohort	  study	  of	  the	  intervention	  group	  in	  the	  trial.	  	  The	  exposure	  variable	  was	  the	  staffing	  pattern	  and	  the	  outcomes	  were	  overall	  protocol	  adherence	  by	  providers	  in	  instances	  where	  changes	  would	  have	  been	  indicated.	  	  
Interventional	  Groups	  at	  each	  site	  The	  data	  on	  nurse	  staffing	  was	  extracted	  by	  retrolectively	  reviewing	  minutes	  from	  the	  monthly	  CanPREVENT	  site	  nurse	  teleconferences	  which	  occurred	  from	  July	  2005	  to	  April	  2008.	  	  These	  meeting	  minutes	  routinely	  documented	  any	  staff	  changes,	  enrollment	  status,	  as	  well	  as	  issues	  relating	  to	  trial	  execution.	  	  The	  nursing	  educational	  background	  and	  clinical	  expertise	  was	  retrospectively	  identified	  with	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each	  interventional	  site.	  	  Each	  interventional	  site	  will	  be	  identified	  using	  an	  alphabetical	  letter	  in	  order	  to	  preserve	  the	  confidentiality	  of	  the	  research	  staff.	  	  The	  summary	  of	  the	  nurse-­‐staffing	  pattern	  is	  as	  follows:	  	  
Relational	  Continuity	  Site	  A	  One	  registered	  nurse	  managed	  the	  interventional	  group	  from	  2005	  to	  the	  end	  of	  the	  study	  in	  2008.	  	  	  	  Site	  B	  	  One	  registered	  nurse	  was	  present	  from	  2005	  until	  February	  of	  2006,	  at	  which	  point	  another	  registered	  nurse	  took	  over	  until	  the	  end	  of	  the	  study	  in	  2008.	  	  	  Site	  C	  A	  registered	  nurse	  who	  was	  a	  clinical	  nurse	  specialist	  with	  a	  master’s	  degree,	  was	  involved	  from	  2005	  until	  the	  end	  of	  the	  study	  in	  2008.	  	  	  Site	  D	  Site	  D	  had	  a	  dedicated	  registered	  nurse	  with	  the	  interventional	  group	  from	  2005	  to	  April	  2007.	  	  She	  was	  subsequently	  replaced	  by	  another	  registered	  nurse	  from	  April	  2007	  to	  Jan	  2008	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Site	  E	  	  Two	  registered	  nurses	  were	  involved	  from	  2005	  until	  the	  Fall	  of	  2006,	  at	  which	  point,	  two	  other	  nurses	  took	  over	  until	  the	  end	  of	  the	  study	  in	  2008.	  	  	  In	  summary,	  only	  Sites	  A	  and	  C	  had	  a	  dedicated	  interventional	  nurse	  from	  the	  beginning	  to	  the	  end	  of	  the	  trial,	  thereby	  providing	  the	  highest	  relational	  continuity	  of	  care.	  	  
Nursing	  educational	  background	  and	  specialty	  training	  Site	  A	  The	  interventional	  nurse	  had	  a	  diploma	  and	  further	  nephrology	  nursing	  certification.	  	  She	  also	  had	  an	  extensive	  background	  in	  nephrology	  nursing.	  	  Site	  B	  The	  interventional	  nurse	  at	  Site	  B	  had	  a	  baccalaureate	  degree	  as	  well	  as	  further	  certification	  in	  nephrology	  nursing.	  	  The	  educational	  background	  of	  the	  other	  nursing	  staff	  are	  unknown.	  	  Site	  C	  The	  interventional	  group	  had	  a	  clinical	  nurse	  specialist	  with	  a	  master's	  degree	  and	  specialty	  expertise	  in	  nephrology	  nursing,	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Site	  D	  Both	  interventional	  nurses	  had	  diploma	  preparation	  in	  nursing.	  	  One	  of	  them	  had	  extensive	  background	  in	  nephrology	  nursing.	  	  Site	  E	  One	  of	  the	  interventional	  nurses	  had	  a	  master’s	  degree	  and	  certification	  in	  nephrology	  nursing.	  	  The	  educational	  background	  of	  the	  other	  three	  nursing	  staff	  members	  is	  unknown.	  	  Please	  see	  Figure	  1	  for	  a	  summary	  of	  the	  interventional	  sites’	  staffing	  description.	  	  Due	  to	  the	  retrospective	  nature	  of	  this	  part	  of	  the	  data	  collection,	  one	  could	  not	  unequivocally	  ascertain	  the	  educational	  background	  and	  expertise	  of	  all	  the	  interventional	  nurses	  at	  each	  study	  site.	  	  	  
Clinical	  parameters	  examined	  The	  surrogate	  end	  point	  or	  treatment	  targets	  specified	  in	  the	  trial	  protocol	  included:	  an	  LDL	  level	  of	  <	  2.5	  mmol/L;	  Hba1c	  of	  <	  7%	  in	  patients	  with	  diabetes	  mellitus;	  a	  blood	  pressure	  target	  of	  <	  130/80	  mmHg;	  weight	  reduction	  in	  obese	  patients;	  antiplatelet	  use	  in	  patients	  with	  a	  history	  of	  ischemic	  disease	  or	  diabetes;	  iron	  saturation	  of	  >	  20%;	  serum	  bicarbonate	  >	  22	  mmol/L;	  serum	  phosphate	  of	  <	  1.8	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mmol/L;	  hemoglobin	  >	  105	  g/L;	  use	  of	  RAAS	  blockers;	  and	  minimization	  of	  proteinuria.	  	  These	  targets	  were	  consistent	  with	  the	  national	  guidelines	  at	  the	  time	  of	  the	  trial	  execution.	  	  	  (The	  trial	  protocol	  detailing	  the	  evidence	  is	  available	  through	  the	  study	  investigator	  upon	  request).	  	  The	  specific	  treatment	  protocols	  in	  the	  CanPREVENT	  study	  were	  categorized	  in	  two	  tiers.	  	  Tier	  one	  interventions	  had	  stronger	  evidence-­‐based	  indications	  and	  were	  more	  likely	  to	  be	  applied	  under	  the	  sole	  direction	  of	  study	  staff	  independently.	  	  They	  included	  antagonism	  of	  the	  renin-­‐angiotensin	  system,	  blood	  pressure	  reduction	  to	  below	  130/80	  mmHg,	  a	  fasting	  LDL	  level	  of	  <	  2.5	  mmol/L,	  using	  aspirin	  for	  cardiovascular	  protection,	  and	  using	  beta-­‐blockers	  in	  those	  with	  heart	  failure	  or	  post	  MI.	  	  	  	  Tier	  two	  therapies	  had	  weaker	  evidence	  and	  normally	  involved	  input	  from	  multiple	  disciplines	  (dietitian,	  nurse	  educator,	  etc.)	  as	  well	  as	  patient	  compliance.	  	  They	  include	  maintenance	  of	  hemoglobin	  level	  between	  105	  g/L	  and	  120	  g/L,	  normalization	  of	  mineral	  metabolism	  parameters,	  and	  avoidance	  of	  malnutrition	  and	  correction	  of	  metabolic	  acidosis.	  	  Medical	  protocols	  were	  developed	  	  that	  addressed	  the	  evidence	  base,	  rationale	  and	  guided	  study	  staff	  in	  aiming	  for	  the	  above	  targets.	  	  At	  the	  outset	  of	  the	  trial,	  an	  orientation	  was	  offered	  to	  all	  nurses	  to	  ensure	  consistency,	  while	  regular	  nationwide	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teleconferences	  were	  conducted	  monthly	  to	  monitor	  and	  update	  progress.	  	  However,	  new	  staff	  was	  not	  given	  the	  same	  orientation	  once	  the	  trial	  was	  underway.	  	  Web-­‐based	  resources	  were	  also	  developed	  as	  guidance	  for	  the	  research	  nursing	  staff.(74)	  	  The	  results	  of	  the	  CANPREVENT	  trial	  were	  published	  previously.(72)	  In	  summary,	  	  the	  rate	  of	  GFR	  decline	  over	  a	  median	  period	  of	  24	  months	  (difference	  in	  marginal	  mean	  1.4cc/min	  per	  1.73m2)	  was	  not	  different	  in	  the	  interventional	  group	  	  comprised	  of	  patients	  attending	  nurse-­‐led	  clinics.	  	  The	  clinical	  endpoints	  included	  cardiovascular	  death,	  all-­‐cause	  mortality,	  ESRD,	  and	  stroke.	  	  The	  overall	  clinical	  endpoints	  rates	  were	  5.3%	  and	  5.2%	  in	  the	  intervention	  and	  control	  groups,	  respectively.	  Amongst	  the	  different	  clinical	  targets:	  a)	  the	  interventional	  group	  had	  a	  slightly	  higher	  average	  number	  of	  antihypertensive	  drugs	  prescribed	  (0.1	  drug,	  p<0.01),	  b)	  	  78%	  interventional	  vs.	  66%	  control	  participants	  were	  on	  RAAS	  blockers	  (p=0.06),	  c)	  intervention-­‐group	  patients	  with	  high	  LDL	  were	  more	  likely	  to	  be	  on	  a	  statin	  (84%	  vs.	  51%,	  p=	  0.0003),	  d)	  as	  were	  interventional-­‐patients	  with	  low	  iron	  saturation	  to	  receive	  iron	  supplementation	  than	  controls	  (35%	  vs.	  14%,	  p=0.005).	  	  Similar	  rates	  were	  observed	  in	  both	  interventional	  and	  control	  groups	  for	  diabetes	  management	  targets	  (referral	  to	  nurse	  educator	  or	  dietitian),	  mineral	  metabolism	  and	  acidosis	  care	  and	  use	  of	  antiplatelet	  therapy.(72)	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With	  the	  diverse	  research	  nurse	  expertise	  and	  staffing	  continuity	  of	  care	  at	  the	  five	  CanPREVENT	  interventional	  sites,	  we	  hypothesized	  that	  the	  addition	  of	  a	  specialized	  clinical	  nurse	  (Site	  C)	  as	  well	  as	  a	  consistent	  and	  continuous	  nursing	  staff	  pattern	  would	  result	  in	  statistically	  significant	  improvements	  in	  adherence	  of	  nurses/team	  to	  pre-­‐defined	  medical	  protocols	  between	  the	  study	  sites.	  	  Six	  clinical	  targets	  related	  to	  dyslipidemia,	  glycemic	  control,	  blood	  pressure,	  weight	  reduction,	  antiplatelet	  usage,	  and	  iron	  supplementation	  will	  be	  examined.	  	  As	  the	  results	  from	  the	  CanPREVENT	  study	  demonstrated	  that	  treatments	  were	  rarely	  required	  for	  anemia,	  metabolic	  acidosis,	  and	  mineral	  metabolism,	  no	  analysis	  will	  be	  performed	  for	  these	  clinical	  benchmarks.	  	  Furthermore,	  the	  resource	  utilization	  by	  interventional	  nurse	  visits	  and	  interventional	  nephrologists	  visits	  amongst	  the	  five	  sites	  will	  also	  be	  compared,	  in	  order	  to	  explore	  whether	  a	  differential	  staffing	  pattern	  translates	  into	  cost	  differences.	  	  The	  analyses	  for	  this	  thesis	  are	  limited	  to	  a	  comparison	  of	  care	  administered	  to	  intervention	  group	  participants	  at	  each	  site,	  as	  control	  groups	  received	  usual	  care	  only	  which	  would	  not	  have	  been	  affected	  by	  study	  staffing	  patterns.	  	  The	  analysis	  of	  this	  was	  performed	  in	  a	  blinded	  fashion.	  	  In	  particular,	  during	  the	  analysis,	  each	  site	  was	  assigned	  an	  arbitrary	  letter	  for	  comparison.	  	  	  	  	  a) Control	  of	  Dyslipidemia	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LDL	  cholesterol	  levels	  were	  measured	  annually	  by	  research	  protocol.	  	  The	  patients	  within	  the	  interventional	  group	  with	  an	  LDL	  level	  of	  above	  2.5	  mmol/L	  and	  who	  were	  not	  on	  a	  statin	  at	  baseline	  were	  identified	  for	  each	  site.	  	  Then,	  it	  was	  determined	  what	  proportion	  of	  this	  subgroup	  were	  started	  on	  a	  statin	  at	  the	  4,	  8	  or	  12	  month	  follow	  up	  visit	  at	  each	  site.	  	  A	  similar	  analysis	  was	  performed	  using	  the	  LDL	  level	  measured	  by	  protocol	  at	  the	  twelve-­‐month	  clinic	  visit.	  	  For	  those	  not	  on	  a	  statin	  at	  the	  12-­‐month	  visit,	  the	  proportion	  so	  prescribed	  within	  the	  following	  12	  months	  was	  determined	  for	  each	  site.	  	  As	  the	  total	  number	  of	  patients	  with	  suboptimal	  LDL	  levels	  and	  not	  on	  appropriate	  treatments	  was	  small,	  the	  results	  from	  the	  first	  and	  second	  year	  analyses	  were	  	  combined	  in	  order	  to	  increase	  the	  numbers	  and	  hence	  the	  power	  of	  the	  analysis.	  	  	  b)	  Diabetic	  Care	  The	  analysis	  began	  by	  analyzing	  the	  number	  of	  diabetic	  patients	  with	  a	  Hemoglobin	  A1c	  above	  7%	  at	  the	  baseline	  clinic	  visit	  and	  twelfth	  month	  clinic	  visit	  in	  the	  intervention	  groups.	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Within	  this	  patient	  population	  where	  their	  glycemic	  control	  was	  above	  target,	  it	  was	  then	  determined	  whether	  any	  of	  these	  patients	  ever	  	  a)	  had	  the	  number	  of	  daily	  insulin	  doses	  increased,	  b)	  had	  the	  number	  of	  their	  oral	  hypoglycemic	  medications	  increased,	  c)	  were	  referred	  to	  a	  diabetic	  clinic,	  d)	  were	  referred	  to	  a	  diabetic	  nurse	  educator,	  e)	  were	  referred	  to	  an	  endocrinologist,	  or	  f)	  were	  referred	  to	  a	  dietitian.	  	  	  For	  instance,	  the	  number	  of	  diabetic	  patients	  with	  an	  HbA1c	  above	  7%	  was	  identified	  at	  the	  baseline	  clinic	  visit.	  	  It	  was	  then	  determined	  if	  any	  of	  the	  diabetic	  patients	  with	  suboptimal	  glycemic	  control	  had	  any	  of	  the	  above	  clinical	  maneuvers	  at	  the	  4th,	  8th	  and	  12th	  month	  clinic	  visits.	  	  Subsequently,	  at	  the	  12th	  month	  clinic	  visit,	  the	  number	  of	  diabetic	  patients	  with	  an	  HbA1c	  level	  above	  7%	  was	  again	  identified.	  	  It	  was	  then	  determined	  if	  any	  of	  these	  patients	  had	  any	  of	  the	  above	  clinical	  interventions	  at	  their	  16th,	  20th	  or	  24th	  clinic	  visits.	  	  	  Due	  to	  the	  fact	  that	  there	  were	  low	  numbers	  of	  patients	  requiring	  any	  of	  the	  above	  interventions,	  we	  also	  examined	  if	  any	  of	  the	  appropriate	  participants	  had	  at	  least	  one	  of	  the	  interventions	  performed	  at	  the	  same	  time	  intervals.	  	  As	  the	  total	  number	  of	  diabetic	  participants	  was	  small,	  the	  results	  from	  the	  first	  and	  second	  year	  analyses	  were	  	  combined	  in	  order	  to	  increase	  the	  numbers	  and	  hence	  the	  power	  of	  the	  analysis.	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c)	  Blood	  pressure	  control	  The	  number	  of	  patients	  who	  had	  blood	  pressure	  readings	  above	  130/80	  mmHg	  at	  the	  baseline	  clinic	  visit,	  twelve	  month	  clinic	  visit	  and	  twenty-­‐fourth	  month	  clinic	  visit	  were	  determined	  in	  the	  intervention	  groups.	  	  This	  the	  only	  analysis	  which	  included	  the	  third	  year	  clinical	  data	  because	  of	  the	  availability	  of	  clinical	  data	  (blood	  pressure	  readings	  and	  medication	  lists)	  which	  was	  collected	  every	  four	  months	  as	  per	  trial	  protocol.	  	  The	  first	  analysis	  involves	  identifying	  the	  number	  of	  patients	  who	  had	  blood	  pressure	  readings	  above	  130/80	  mmHg	  at	  baseline	  clinic	  visit	  and	  had	  their	  number	  of	  antihypertensive	  medications	  adjusted	  upward	  at	  any	  point	  within	  the	  first	  twelve	  months.	  	  The	  second	  analysis	  involves	  identifying	  the	  number	  of	  patients	  who	  had	  a	  blood	  pressure	  reading	  above	  130/80	  mmHg	  at	  the	  twelfth	  month	  clinic	  visit	  and	  had	  their	  number	  of	  antihypertensive	  medications	  increased	  at	  any	  point	  between	  the	  twelfth	  and	  twenty-­‐fourth	  month.	  	  A	  third	  analysis	  identifies	  the	  number	  of	  patients	  who	  had	  a	  blood	  pressure	  reading	  above	  130/80	  at	  the	  twenty-­‐fourth	  month	  clinic	  visit	  and	  had	  their	  number	  of	  antihypertensive	  medications	  increased	  at	  any	  point	  between	  the	  twenty-­‐fourth	  and	  thirty-­‐sixth	  month.	  	  As	  the	  total	  number	  of	  suboptimal	  treated	  hypertensive	  participants	  was	  small,	  the	  results	  of	  the	  first,	  second	  and	  third	  year	  analyses	  were	  combined	  to	  increase	  the	  power	  of	  the	  overall	  analysis.	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  d)	  Weight	  reduction	  Any	  patients	  with	  a	  body	  mass	  index	  of	  above	  30	  were	  identified.	  	  It	  was	  then	  determined	  whether	  any	  of	  these	  patients	  were	  referred	  to	  a	  dietitian	  at	  any	  point	  from	  the	  start	  of	  the	  study	  to	  the	  24th	  month	  of	  the	  study.	  	  e)	  Antiplatelet	  Use	  Any	  patients	  with	  a	  clinical	  indication	  for	  antiplatelet	  use	  were	  identified.	  	  The	  indications	  included	  having	  a	  history	  of	  coronary	  artery	  disease	  (prior	  myocardial	  infarction,	  prior	  angina,	  prior	  percutaneous	  transluminal	  coronary	  angioplasty,	  and/or	  prior	  history	  of	  coronary	  artery	  bypass	  graft)	  having	  diabetes	  mellitus,	  having	  a	  history	  of	  peripheral	  vascular	  disease	  (prior	  gangrene,	  prior	  amputation,	  experiencing	  intermittent	  claudication	  and/or	  history	  of	  bypass	  intervention),	  and/or	  prior	  cerebral	  vascular	  accident	  (history	  of	  transient	  ischemic	  attacks	  and/or	  history	  of	  thrombotic	  stroke).	  	  From	  this	  group	  of	  patients,	  it	  was	  then	  determined	  if	  any	  of	  them	  were	  ever	  on	  an	  antiplatelet	  medication	  during	  the	  study.	  	  The	  number	  of	  patients	  with	  at	  least	  one	  cardiovascular	  indication	  who	  were	  started	  on	  an	  antiplatelet	  agent	  during	  the	  first	  24	  months	  of	  the	  study	  was	  also	  determined.	  	  The	  number	  of	  patients	  who	  were	  not	  on	  an	  antiplatelet	  agent	  due	  to	  a	  past	  history	  of	  gastrointestinal	  bleeding	  was	  also	  noted.	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  f)	  Use	  of	  Iron	  supplementation	  in	  appropriate	  patients	  Patients	  with	  an	  iron	  saturation	  level	  below	  20%	  were	  identified	  from	  the	  database	  at	  the	  baseline	  clinic	  visit.	  	  Among	  these,	  we	  then	  determined	  whether	  the	  patients	  were	  ever	  started	  on	  oral	  or	  intravenous	  iron	  supplementation	  between	  0	  to	  24	  months	  of	  the	  study.	  	  	  g)	  Combined	  intervention	  analysis	  –	  the	  above	  six	  clinical	  interventions	  were	  combined	  for	  further	  analysis.	  	  One	  analysis	  was	  performed	  comparing	  sites	  using	  a	  Chi-­‐squared	  test	  in	  terms	  of	  the	  total	  number	  of	  interventions	  completed	  in	  circumstances	  where	  the	  protocol	  would	  have	  suggested	  them.	  	  This	  Chi-­‐squared	  test	  included	  all	  the	  possible	  interventions	  as	  denominator,	  and	  thus	  could	  have	  counted	  multiple	  instances	  for	  specific	  participants.	  	  It	  is	  recognized	  that	  this	  violates	  the	  principle	  of	  independence,	  but	  it	  maximizes	  power.	  	  In	  contrast	  the	  second	  analysis	  was	  performed	  with	  a	  logistic	  regression	  (explained	  later)	  to	  compare	  sites	  in	  terms	  of	  whether	  indicated	  interventions	  were	  carried	  out	  or	  not	  and	  for	  this	  analysis	  each	  participant	  could	  only	  contribute	  once.	  	  The	  consistency	  of	  the	  results	  will	  be	  compared	  across	  both	  analytic	  approaches.	  	  h)	  Health	  Care	  Utilization	  and	  Costs	  The	  program	  costs	  per	  year	  per	  patient	  were	  estimated	  separately	  for	  study	  nurses	  and	  nephrologists.	  	  The	  data	  for	  use	  of	  nursing	  resources	  was	  more	  comprehensive	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than	  the	  nephrologist	  resources	  because	  each	  nursing	  visit	  was	  recorded	  in	  the	  CANPREVENT	  trial	  database	  as	  well	  as	  nursing	  logs.	  	  The	  nephrologists	  were	  required	  to	  complete	  four	  2-­‐week	  block	  logs	  for	  a	  total	  of	  eight	  weeks,	  while	  the	  nurses	  were	  required	  to	  complete	  logs	  for	  six	  randomly	  selected	  days	  during	  the	  study.	  	  The	  data	  for	  nephrologists'	  time	  spent	  was	  less	  accurate	  as	  it	  relied	  on	  nephrologists’	  self–reported	  log	  sheets	  which	  were	  not	  always	  completed	  on	  schedule.	  	  For	  instance,	  the	  nephrologist	  at	  Site	  C	  did	  not	  complete	  the	  activity	  log	  and	  only	  reported	  weekly	  time	  spent	  after	  the	  conclusion	  of	  the	  trial.	  	  One	  site	  nephrologist	  submitted	  only	  four	  weekly	  logs	  while	  the	  remaining	  three	  site	  nephrologists	  submitted	  eight	  weekly	  logs.	  	  Overall,	  the	  nurses’	  logs	  were	  63%	  reported	  while	  the	  nephrologists’	  logs	  were	  70%	  reported.	  	  Even	  though	  the	  nurses’	  logs	  were	  less	  complete	  than	  the	  physicians’	  logs,	  each	  nursing	  visit	  was	  tracked	  in	  the	  study,	  enabling	  a	  more	  accurate	  calculation	  of	  the	  nursing	  resource	  utilization.	  	  For	  the	  nephrologists’	  cost,	  the	  nephrologists	  at	  each	  site	  completed	  timing	  logs	  to	  record	  all	  events	  related	  to	  care	  for	  the	  study	  patients	  during	  several	  randomly	  selected	  two-­‐week	  periods	  at	  different	  points	  during	  the	  trial.	  	  This	  included	  the	  extra	  time	  for	  meetings,	  communications	  (emails	  and	  telephone	  calls)	  relating	  to	  patient	  care	  and	  direct	  patient	  contacts.	  	  The	  sampling	  logs	  generated	  the	  average	  time	  per	  week	  spent	  by	  each	  nephrologist	  at	  each	  site.	  	  This	  number	  was	  then	  multiplied	  by	  104	  weeks	  (two	  years	  or	  the	  duration	  of	  the	  study).	  Costs	  were	  then	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calculated	  by	  multiplying	  time	  by	  the	  physician	  fee	  ($45.85)	  for	  a	  20-­‐minute	  repeat	  consultation	  according	  to	  the	  Ontario	  physicians’	  payment	  schedule.	  	  	  	  For	  the	  nursing	  costs,	  the	  time	  logs	  for	  each	  nurse	  at	  each	  site	  generated	  an	  average	  time	  per	  visit	  across	  all	  the	  sites	  (69.3	  minutes/visit),	  which	  was	  then	  multiplied	  by	  the	  average	  number	  of	  visits	  over	  the	  course	  of	  the	  study,	  and	  then	  multiplied	  by	  the	  maximum	  wage	  that	  an	  Ontario	  registered	  nurse	  receives	  ($40	  per	  hour).(73)	  	  See	  Figure	  2	  for	  a	  summary	  of	  the	  study	  design.	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Site	   Relational	  Continuity	  /	  
Staffing	  consistency	  




A	   1	   -­‐Diploma	  with	  nursing	  cerfication	  
B	   2	   -­‐Baccalaureate	  degree	  	  -­‐Other	  unknown	  
C	   1	   -­‐Master’s	  Degree	  with	  nursing	  certification	  
D	   2	   -­‐Diploma	  with	  nephrology	  experience	  	  -­‐Other	  with	  Diploma	  
E	   4	   -­‐Master’s	  Degree	  	  -­‐Other	  three	  unknown	  	  Figure	  1	  –	  Summary	  of	  the	  Interventional	  Sites’	  Staffing	  Description	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CanPREVENT	  (Canadian	  Collaborative	  Group	  for	  the	  Prevention	  of	  Renal	  and	  Cardiovascular	  Endpoints	  Trial)	  (2005	  to	  2008)	  N	  =	  474	  
Interventional	  sites:	  Examine	  each	  sites’	  staffing	  pattern	  based	  on	  meeting	  minutes,	  research	  protocol,	  and	  retrospective	  identification	  	   	  
Control	  (Usual	  care)	  	  	  N	  =	  236	  
-­‐Upon	  completion	  of	  trial,	  noted	  different	  provider	  adherence	  patterns	  by	  each	  interventional	  site	  -­‐Some	  sites	  had	  more	  research	  staff	  turnover	  -­‐Research	  nurses	  had	  different	  educational	  background	  and	  clinical	  expertise	  
Hypothesized	  that	  the	  pattern	  of	  research	  staffing	  would	  affect	  defined	  clinical	  protocol	  adherence,	  tested	  by	  further	  examining	  each	  interventional	  site	  
Site	  A	  1	  nurse	  	  	  diploma	  nephrology	  certification	   	  
Site	  	  B	  2	  nurses	  	  BN	  Nephrology	  certification	  	  Other	  unknown	  
Site	  C	  1	  nurse	  	  masters	  	  
Site	  D	  2	  nurses	  	  diplomas	  	  	  
Site	  E	  4	  nurses	  	  masters	  nephrology	  certification	  	  others	  unknown	  
Intervention	  (Usual	  care	  plus	  additional	  nursing	  care	  focused	  on	  risk	  factor	  modification)	  N	  =238	  
Examined	  adherence	  to	  various	  defined	  clinical	  protocols	  and	  cost	  analysis:	  dyslipidemia	  control,	  diabetic	  control,	  hypertension	  control,	  weight	  management,	  antiplatelet,	  and	  iron	  use.	  	  
Figure	  2	  –	  Overview	  of	  study	  design	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Statistical	  analysis	  The	  study	  group	  characteristics	  were	  described	  as	  proportions,	  median	  (interquartile	  range)	  or	  means	  (standard	  deviation)	  as	  appropriate.	  	  Proportions	  were	  compared	  by	  χ2	  .	  	  The	  means	  were	  compared	  by	  t	  tests	  or	  ANOVA	  (for	  >	  2	  samples).	  	  Medians	  were	  compared	  by	  a	  median	  test.	  	  Analysis	  of	  data	  across	  sites	  was	  completed	  with	  the	  investigator	  blinded	  as	  to	  site.	  	  In	  stating	  the	  results,	  each	  site	  will	  be	  identified	  by	  an	  alphabetical	  letter	  in	  order	  to	  preserve	  the	  confidentiality	  of	  the	  research	  staff.	  	  	  	  A	  logistic	  regression	  model	  was	  employed	  to	  evaluate	  the	  association	  between	  study	  sites	  and	  combined	  overall	  protocol	  adherence	  (explained	  later).	  	  Since	  a	  non-­‐linear	  model	  was	  employed,	  confidence	  intervals	  that	  included	  1	  were	  considered	  as	  non-­‐significant.	  	  Model	  significance	  was	  tested	  by	  the	  Omnibus	  test,	  Hosmer-­‐Lemeshow	  test	  and	  -­‐2loglinear	  likelihood	  ratios.	  	  Cox-­‐Snell	  R2	  and	  Nagelkerke	  R2	  were	  considered	  as	  the	  equivalent	  to	  R2	  in	  the	  linear	  regression.	  	  Significance	  of	  individual	  coefficients	  were	  tested	  using	  Wald	  statistic	  technique,	  and	  odds	  ratios	  with	  95%	  confidence	  intervals	  (CI)	  were	  obtained.	  	  Assumptions	  were	  tested,	  and	  residual	  analysis	  was	  performed	  to	  evaluate	  the	  model.	  	  A	  deviation	  contrast	  method	  was	  selected	  to	  compare	  each	  category	  of	  the	  predictor	  variable	  (except	  the	  reference	  category)	  to	  the	  overall	  effect.	  	  	  	  All	  of	  the	  data	  were	  analyzed	  using	  SPSS	  (version	  18.0.2).	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RESULTS	  	  Within	  the	  intervention	  groups,	  there	  were	  54	  patients	  enrolled	  at	  Site	  A,	  59	  patients	  at	  Site	  B,	  60	  patients	  at	  Site	  C,	  29	  patients	  at	  Site	  D	  and	  36	  patients	  at	  Site	  E,	  giving	  a	  total	  of	  238	  patients	  in	  the	  intervention	  group	  amongst	  the	  five	  sites.	  	  	  Their	  baseline	  characteristics	  are	  described	  in	  Table	  1.	  	  The	  trial	  ran	  from	  May	  2005	  to	  June	  2008.	  	  The	  median	  follow-­‐up	  was	  2.03	  years	  (1.68	  –	  2.34).	  	  Within	  each	  particular	  site,	  the	  median	  follow-­‐up	  at	  Site	  A	  was	  1.78	  years	  (1.13-­‐2.40),	  at	  Site	  B	  was	  1.83	  years	  (1.13-­‐2.53),	  at	  Site	  C	  was	  1.92	  years	  (1.28-­‐2.55),	  at	  Site	  D	  was	  1.56	  years	  (0.83-­‐2.29)	  and	  at	  Site	  E	  was	  1.47	  years	  (1.04	  –	  1.90)	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Table	  1	  Baseline	  characteristics	  of	  interventional	  trial	  participants	  at	  each	  site.	  	  	  	  	   Site	  A	  (N-­‐54)	   Site	  B	  (N=59)	   Site	  C	  (N=60)	   Site	  D	  (N=29)	   Site	  E	  (N=36)	   P	  Values	  for	  the	  Difference	  The	  following	  are	  continuous	  variables	  presented	  as	  median	  (interquartile	  range)	   	  Age	   66	  (58-­‐69)	   63(58-­‐69)	   69(65-­‐72)	   66(59-­‐72)	   69(64-­‐74)	   0	  Creatinine	  (μmol/L)	   136(118-­‐150)	   119(110-­‐138)	   122(106-­‐138)	   134(117-­‐145)	   118(106-­‐134)	   0	  Baseline	  eGFR	  (mls/min/1.73m2)	   43(37-­‐46)	   43(39-­‐47)	   44(40-­‐48)	   41(35-­‐43)	   40(36-­‐44)	   0.023	  Weight	  (kg)	   90(77-­‐98)	   84(75-­‐102)	   74(63-­‐89)	   86(74-­‐94)	   81(67-­‐92)	   0.063	  Systolic	  blood	  pressure	   128(113-­‐135)	   126(113-­‐132)	   140(120-­‐150)	   122(116-­‐132)	   125(117-­‐134)	   0.075	  Diastolic	  blood	  pressure	   70(63-­‐80)	   76(70-­‐82)	   77(65-­‐80)	   78(64-­‐80)	   73(68-­‐79)	   0.032	  Proteinuria	  (g/Day)	   0.12(0.06-­‐0.22)	   0.12(0.06-­‐0.19)	   0.10(0.06-­‐0.15)	   0.13(0.06-­‐0.18)	   0.08(0.05-­‐0.11)	   0	  LDL	  cholesterol	  (mmol/L)	   2.5(2.0-­‐3.5)	   2.7(2.2-­‐3.5)	   2.6(2.0-­‐3.3)	   2.4(1.8-­‐3.3)	   2.7(2.1-­‐3.4)	   0.723	  Hba1c	  among	  diabetics	  (%)	   6.8(6.4-­‐7.5)	   7.0(6.8-­‐8.5)	   7.2(6.2-­‐8.0)	   7.9(6.8-­‐8.3)	   6.3(6.2-­‐6.6)	   0	  Hemoglobin	  (g/L)	   138(124-­‐147)	   138(129-­‐146)	   134(118-­‐142)	   134(126-­‐147)	   138(122-­‐149)	   0.12	  The	  following	  are	  binary	  variables	  presented	  as	  a	  frequency	  number	  (percentage)	   	  Female	   24(44)	   41(70)	   30(50)	   13(45)	   23(64)	   0.034	  Caucasian	   53(98)	   56(95)	   53(88)	   29(100)	   32(89)	   0.380	  Retired	   32(59)	   30(51)	   44(73)	   16(55)	   22(61)	   0.269	  Working	   14(24)	   15(25)	   10(17)	   7(24)	   12(33)	   0.269	  Post-­‐Secondary	  school	  Education	   24(44)	   19(32)	   21(35)	   13(45)	   19(53)	   0.071	  Married	   45(83)	   35(59)	   33(55)	   23(79)	   23(64)	   0.230	  Living	  in	  own	  Home	  –	  no	  hired	  assistance	   50(93)	   58(98)	   55(92)	   28(97)	   33(92)	   0.814	  Current	  Smoker	   7(13)	   3(5)	   7(12)	   2(7)	   1(3)	   0.571	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Systolic	  BP	  >	  130	  mmHg	   19(35)	   21(36)	   34(57)	   16(55)	   19(53)	   0.049	  Systolic	  BP≥	  140	  mmHg	   9(17)	   13(22)	   24(40)	   8(28)	   11(30)	   0.062	  Diastolic	  BP	  >	  80	  mmHg	   8(15)	   12(20)	   16(27)	   15(52)	   13(36)	   0.003	  Diastolic	  BP	  ≥	  90	  mmHg	   2(4)	   4(7)	   4(7)	   4(14)	   4(11)	   0.473	  Diabetes	  Mellitus	   22(41)	   16(27)	   19(32)	   9(31)	   7(19)	   0.278	  Angina	   6(11)	   6(10)	   1(2)	   3(10)	   3(8)	   0.054	  History	  of	  Myocardial	  Infarction	   9(17)	   6(10)	   12(20)	   7(24)	   5(14)	   0.458	  History	  of	  PTCA	   4(7)	   3(5)	   8(13)	   5(17)	   6(17)	   0.215	  History	  of	  CABG	   10(18)	   0(0)	   7(12)	   4(14)	   4(11)	   0.025	  History	  of	  Heart	  Failure	   6(11)	   2(3)	   4(7)	   0(0)	   1(3)	   0.195	  History	  of	  Cardiac	  Arrhythmia	   11(20)	   8(14)	   6(10)	   3(10)	   4(11)	   0.351	  History	  of	  cerebrovascular	  event	   1(2)	   0(0)	   3(5)	   1(3)	   1(3)	   0.634	  History	  of	  Hypertension	   42(78)	   47(80)	   48(80)	   21(72)	   24(67)	   0.378	  History	  of	  Chronic	  Lung	  Disease	   5(9)	   4(7)	   6(10)	   0(0)	   3(8)	   0.558	  History	  of	  Cancer	   5(9)	   6(10)	   7(12)	   2(7)	   7(19)	   0.465	  Taking	  an	  ACE	  inhibitor	  or	  ARB	   42(78)	   45(76)	   37(62)	   17(59)	   24(67)	   0.165	  Taking	  a	  statin	   31(57)	   28(49)	   32(53)	   13(45)	   13(36)	   0.338	  	  	  The	  baseline	  characteristics	  amongst	  the	  five	  study	  sites	  demonstrated	  that	  Site	  B	  had	  the	  youngest	  patients	  proportionally	  compared	  to	  the	  rest	  of	  the	  sites	  and	  it	  had	  the	  highest	  proportion	  of	  female	  participants,	  while	  Sites	  A	  and	  D’s	  participants	  had	  higher	  baseline	  creatinine	  levels	  when	  compared	  to	  the	  rest.	  	  The	  baseline	  diastolic	  blood	  pressure	  readings	  were	  lowest	  at	  Site	  A.	  	  Among	  diabetic	  participants,	  Site	  D	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patients	  had	  the	  highest	  HbA1c	  levels.	  	  Site	  D	  also	  had	  the	  highest	  proportion	  of	  participants	  with	  diastolic	  blood	  pressure	  reading	  above	  80	  mmHg,	  while	  Site	  A	  had	  the	  lowest	  proportion	  of	  participants	  with	  systolic	  blood	  pressure	  readings	  above	  130	  mmHg.	  	  Site	  E	  had	  the	  lowest	  levels	  of	  proteinuria	  compared	  to	  the	  rest.	  	  Regarding	  comorbidities,	  Site	  C	  had	  the	  lowest	  proportions	  of	  participants	  with	  current	  angina,	  and	  Site	  B	  had	  the	  lowest	  proportions	  of	  participants	  with	  history	  of	  CABG.	  	  Even	  though	  there	  were	  baseline	  differences	  between	  the	  interventional	  sites,	  limiting	  the	  analysis	  to	  interventions	  provided	  to	  suboptimally	  treated	  participants	  will	  mitigate	  the	  bias	  generated	  by	  the	  differences.
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Table	  2	  Comparison	  of	  Dyslipidemia	  control	  between	  the	  five	  interventional	  sites	  	  The	  first	  row	  lists	  the	  number	  and	  percentage	  of	  patients	  with	  a	  suboptimal	  LDL	  level	  at	  the	  beginning	  of	  the	  study	  or	  at	  twelve	  months	  of	  the	  study.	  	  The	  following	  row	  lists	  the	  number	  of	  suboptimal	  patients	  not	  on	  a	  statin.	  	  	  The	  following	  row	  then	  lists	  the	  number	  and	  percentage	  of	  those	  patients	  started	  on	  a	  statin	  during	  their	  first	  two	  years	  of	  the	  study.	  	  Site	   Site	  A	  N=53	   Site	  B	  N=57	   Site	  C	  N=58	   Site	  D	  N=29	   Site	  E	  N=33	   Chi	  square	   p-­‐value	  Patients	  with	  LDL	  Level	  >	  2.5	  mmol	  at	  baseline	  or	  at	  twelve	  months	  
38	  (71.7)	  	  
47	  (82.4)	   41	  	  (70.7)	   25	  (86.2)	   24	  	  (72.7)	   4.60	   0.33	  
Patients	  not	  on	  a	  statin	  at	  baseline	  with	  LDL	  level	  >	  2.5	  mmol/L	  
20/38	  	  (52.6)	   24/47	  (51.1)	   21/41	  	  (51.2)	   18/31	  (58.1)	   22/24	  	  (91.7)	   13.32	   0.01	  
Started	  on	  a	  statin	  within	  the	  first	  two	  years	  	  
8/20	  	  (40)	   13/24	  (54.2)	   16/21	  	  (76.2)	   6/18	  (33.3)	   5/22	  	  (22.7)	   14.61	   0.006	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This	  analysis	  revealed	  that	  Site	  E	  had	  the	  highest	  proportion	  of	  participants	  with	  an	  LDL	  level	  above	  target	  range	  that	  was	  not	  treated	  with	  a	  statin.	  	  It	  also	  showed	  that	  Site	  C	  had	  the	  highest	  percentage	  of	  participants	  (76.2%)	  correctly	  started	  on	  a	  statin	  during	  the	  first	  two	  years	  of	  the	  study.	  	  Both	  Sites	  D	  and	  E	  had	  the	  lowest	  number	  of	  participants	  started	  on	  a	  statin	  appropriately.	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Table	  3	  Comparison	  of	  Diabetic	  care	  at	  the	  five	  interventional	  sites	  	  The	  first	  row	  describes	  the	  number	  of	  participants	  with	  suboptimal	  HbA1c.	  	  The	  following	  rows	  list	  the	  number	  of	  participants	  who	  had	  their	  insulin	  regime	  intensified,	  oral	  hypoglycemic	  increased,	  diabetic	  clinic	  visit,	  diabetic	  educator	  visit,	  endocrinologist	  visit,	  dietitian	  visit,	  or	  any	  one	  of	  those	  interventions	  respectively.	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   Site	  A	  (N=22)	   Site	  B	  (N=16)	   Site	  C	  (N=19)	   Site	  D	  (N=9)	   Site	  E	  (N=7)	   Chi	  	  square	   p-­‐value	  Number	  of	  diabetic	  patients	  with	  HbA1C	  >	  7%	  at	  baseline	  or	  at	  twelve	  months	  
12	  (54.5)	   10(62.5)	   13	  (68.4)	   7	  (77.8)	   0	   12.16	   0.016	  
Had	  insulin	  regime	  intensified	  
2/12	  (16.7)	   0	   1/13	  (7.8)	   0	   	   2.955	   0.40	  
Had	  number	  of	  oral	  hypoglycemic	  increased	  
1/12	  (8.3)	   1/10	  (10)	   3/13	  (23.1)	   0	   	   2.674	   0.44	  
Had	  at	  least	  one	  diabetic	  clinic	  visit	  
3/12	  (25)	   5/10	  (50)	   1/13	  (7.8)	   4/7	  	  (57.1)	   	   7.434	   0.06	  
Had	  at	  least	  one	  diabetes	  educator	  visit	  
5/12	  (41.7))	   3/10	  (30)	   2/13	  (15.4)	   5/7	  (71.4)	   	   6.556	   0.09	  
Had	  at	  least	  one	  endocrinologist	  visit	  
1/12	  (8.3)	   3/10	  (30)	   1/13	  (7.8)	   3/7	  	  (42.8)	   	   5.332	   0.15	  
Had	  at	  least	  one	  dietitian	  visit	   5/12	  (41.7)	   3/10	  (30)	  	   2/13	  (15.4)	   5/7	  (71.4)	  	   	   6.556	   0.09	  Had	  any	  above	  interventions	   7/12	  (58.3)	   5/10	  (50)	   7/13	  (53.8)	   5/7	  	  (71.4)	   	   0.856	   0.84	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All	  sites	  had	  low	  numbers	  of	  enrolled	  diabetic	  participants,	  and	  an	  even	  lower	  number	  of	  participants	  with	  HbA1c	  >7%.	  	  This	  generally	  translated	  into	  a	  low	  number	  of	  diabetic	  therapeutic	  changes	  and	  referrals	  to	  diabetic	  clinics.	  	  This	  analysis	  demonstrated	  that	  there	  were	  large	  variations	  of	  diabetic	  control	  among	  diabetic	  participants	  across	  the	  sites.	  	  For	  instance,	  none	  of	  the	  diabetic	  patients	  at	  Site	  E	  had	  an	  HbA1c%	  level	  above	  target	  range,	  while	  Site	  D	  had	  77.8%	  of	  diabetic	  participants	  above	  the	  target	  range	  (p-­‐value	  =	  0.016).	  	  None	  of	  the	  observed	  practice	  patterns	  in	  the	  four	  sites	  for	  suboptimal	  diabetic	  patients	  was	  statistically	  significantly	  different	  across	  sites	  during	  the	  two	  years	  of	  the	  study.
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Table	  4	  Comparison	  of	  blood	  pressure	  management	  at	  the	  five	  interventional	  sites	  	  In	  the	  following	  tables	  the	  first	  row	  shows	  the	  number	  and	  percentage	  of	  participants	  with	  a	  blood	  pressure	  reading	  above	  130/80	  mmHg	  at	  their	  baseline	  clinical	  visit,	  at	  the	  twelve	  month	  clinic	  visit,	  or	  at	  their	  24th	  month	  clinic	  visit.	  	  	  This	  is	  followed	  by	  the	  number	  and	  percentage	  of	  those	  participants	  who	  had	  the	  number	  of	  antihypertensive	  medications	  increased	  during	  the	  subsequent	  year	  of	  the	  study.	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   Site	  A	  (N=54)	   Site	  B	  (N=57)	   Site	  C	  (N=60)	   Site	  D	  (N=29)	   Site	  E	  (N=36)	   Chi	  Square	   p-­‐value	  Number	  of	  patients	  with	  blood	  pressure	  above	  130/80	  mmHg	  at	  baseline,	  twelve	  months,	  or	  twenty-­‐four	  months	  
22	  (40.7)	   38	  (66.7)	   43	  (71.7)	   17	  (58.6)	   19	  (52.8)	   13.37	   0.01	  
Number	  of	  patients	  who	  had	  number	  of	  medications	  increased	  during	  the	  first,	  second	  or	  third	  12	  months	  	  of	  the	  study	  
10/22	  (45.4)	   11/38	  (28.9)	   8/43	  (18.6)	   2/17	  (11.8)	   7/19	  (36.8)	   8.275	   0.08	  
	  This	  analysis	  demonstrated	  that	  during	  the	  study,	  the	  participants	  at	  Site	  C	  had	  the	  highest	  percentage	  (71.7%)	  of	  patients	  with	  suboptimal	  blood	  pressure	  readings	  at	  baseline,	  twelve	  months	  and	  24	  months.	  	  Site	  A	  had	  the	  highest	  percentage	  of	  participants	  with	  the	  number	  of	  antihypertensive	  medications	  increased	  (45.4%),	  although	  this	  was	  only	  a	  trend	  and	  not	  statistically	  significant	  (p=0.08).	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Table	  5	  Comparison	  of	  Overweight	  management	  at	  the	  five	  interventional	  sites	  	  The	  first	  row	  of	  the	  table	  describes	  the	  number	  and	  percentage	  of	  participants	  with	  a	  BMI	  of	  >30	  at	  each	  interventional	  site.	  	  The	  second	  row	  presents	  the	  number	  and	  percentage	  of	  overweight	  patients	  who	  were	  referred	  to	  a	  dietitian	  during	  the	  course	  of	  the	  study.	  	  	   Site	  A	  N=(54)	   Site	  B	  	  	  	  N	  =	  (59)	   Site	  C	  N=(60)	   Site	  D	  N=(29)	   Site	  E	  N=(36)	   Chi	  Square	   p-­‐value	  BMI	  >	  30	  at	  baseline	   31	  (57.4)	   34	  (57.6)	   19	  (31.7)	   11	  (37.9)	   15	  (41.7)	   12.02	   0.017	  Number	  of	  patients	  with	  at	  least	  one	  dietitian	  visit	  during	  the	  study	  
11/31	  (35.5)	   12/34	  (35.3)	   3/19	  (15.8)	   6/11	  (54.4)	   3/15	  	  (20)	   6.216	   0.18	  
	  The	  analysis	  showed	  that	  Site	  B	  had	  the	  highest	  percentage	  of	  patients	  with	  a	  BMI	  >	  30	  (57.6%),	  followed	  by	  Site	  A.	  	  There	  was	  a	  higher	  proportion	  of	  participants	  at	  Site	  D	  referred	  to	  a	  dietitian	  (54.4%)	  and	  a	  lower	  proportion	  of	  participants	  at	  Site	  C	  referred	  to	  a	  dietitian	  (15.8%).	  	  However,	  these	  differences	  in	  proportions	  are	  not	  statistically	  significant.	  
	   46	  
Table	  6	  	  	  	  Comparison	  of	  Antiplatelet	  prescription	  at	  the	  five	  interventional	  sites	  	  The	  first	  row	  of	  the	  table	  describes	  the	  number	  of	  participants	  with	  at	  least	  one	  cardiovascular	  disease	  or	  diabetes.	  	  The	  second	  row	  eliminated	  those	  participants	  with	  a	  contraindication	  for	  antiplatelet	  therapy	  (GI	  bleed).	  	  The	  next	  row	  lists	  the	  number	  of	  participants	  with	  cardiovascular	  disease	  without	  a	  contraindication	  (GI	  Bleed)	  and	  not	  on	  an	  antiplatelet.	  	  The	  final	  row	  describes	  the	  number	  of	  patients	  started	  on	  an	  antiplatelet	  during	  the	  study.	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   Site	  A	  N	  =	  (54)	  
Site	  B	  	  N	  =	  (59)	   Site	  C	  N	  =	  (60)	   Site	  D	  N	  =	  (29)	   Site	  E	  N	  =	  (36)	   Chi	  Square	   p-­‐value	  
Patients	  with	  indication	  for	  antiplatelet	  use	  
33	  (61.1)	   28	  (47.4)	   31	  (51.7)	   17	  (58.6)	   16	  (44.4)	   3.596	   0.46	  
Patients	  with	  cardiovascular	  indication	  without	  a	  history	  of	  GI	  Bleed	  
30	  (55.6)	   28	  (47.4)	   31	  (51.7)	   16	  (55.2)	   16	  (44.4)	   1.574	   0.81	  
Number	  of	  patients	  not	  on	  an	  antiplatelet	  at	  baseline	  
5	  (16.7)	   5	  (17.8)	   1	  (3.2)	   6	  (37.5)	   3	  (18.8)	   9.17	   0.057	  
Number	  of	  patients	  with	  cardiovascular	  indication,	  without	  GI	  bleed	  started	  on	  an	  antiplatelet	  during	  the	  trial	  in	  24	  months	  
1/5	  (20)	   5/5	  (100)	   0	   0	  	   2/3	  (66.7)	   13.89	   0.08	  
	  Site	  B	  had	  the	  highest	  proportion	  of	  participants	  started	  on	  antiplatelet	  therapy	  correctly	  (100%),	  although	  this	  was	  not	  statistically	  significant	  (p=0.08).	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Table	  7	  	  	  Comparison	  of	  Iron	  replacement	  therapy	  between	  the	  five	  interventional	  sites	  	  The	  first	  row	  describes	  the	  number	  and	  percentage	  of	  participants	  with	  evidence	  of	  iron	  deficiency	  (based	  on	  an	  iron	  saturation	  level	  below	  20%	  at	  the	  baseline	  clinic	  visit	  or	  at	  12	  months).	  	  The	  second	  row	  describes	  the	  number	  and	  percentage	  of	  participants	  with	  iron	  deficiency	  and	  not	  on	  iron	  supplementation.	  	  Row	  three	  describes	  the	  number	  and	  percentage	  of	  such	  participants	  started	  on	  iron	  supplementation	  during	  the	  first	  two	  years	  of	  the	  study.	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   Site	  A	   Site	  B	   Site	  C	   Site	  D	   Site	  E	   Chi	  square	   p-­‐value	  Patients	  with	  Iron	  Saturation	  <	  20%	  at	  baseline	  or	  at	  12	  months	  
N	  =	  54	   N	  =59	   N	  =60	   N	  =29	   N	  =36	  23	   30	   23	   11	   12	   3.536	   0.47	  
Participants	  with	  Iron	  Saturation	  <	  20%	  and	  not	  on	  Iron	  at	  Baseline	  
19/23	  (82.6)	   17/30	  (56.7)	   19/23	  (82.6)	   9/11	  (81.8)	   6/12	  (50)	   9.141	   0.058	  
Number	  of	  patients	  started	  on	  Iron	  replacement	  during	  the	  first	  24	  months	  of	  the	  study	  
4/19	  (21)	   13/17	  (76.4)	   3/19	  (15.8)	   1/9	  (11.1)	   5/6	  (16.7)	   25.18	   0.00005	  
	  This	  analysis	  demonstrates	  that	  Site	  B	  had	  the	  highest	  number	  and	  percentage	  of	  participants	  started	  on	  iron	  supplementation	  appropriately	  (76.4%)	  which	  was	  statistically	  significant	  (p=0.00005).	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  Table	  8	  	  Summary	  of	  the	  key	  interventions	  and	  their	  combined	  analysis	  Site	   Site	  A	   Site	  B	   Site	  C	   Site	  D	  	   Site	  E	   Chi-­‐square	   p-­‐value	  Dyslipidemia	  Intervention	  	   8/20	  	  (40%)	   13/24	  (54.2%)	   16/21	  	  (76.2%)	   6/18	  (33.3%)	   5/22	  	  (22.7%)	   14.61	   0.006	  Diabetes	  Intervention	   7/12	  (58.3%)	   5/10	  (50%)	   7/13	  	  (53.8%)	   5/7	  	  (71.4%)	   0	   0.856	   0.84	  BP	  Intervention	   10/22	  (45.4%)	   11/38	  (28.9%)	   8/43	  (18.6%)	   2/17	  (11.8%)	   7/19	  	  (36.8%)	   8.275	   0.08	  BMI	  Intervention	   11/31	  (35.5%)	   12/34	  (35.3%)	   3/19	  	  (15.8%)	   6/11	  (54.4%)	   3/15	  	  (20%)	   6.216	   0.18	  Antiplatelet	  Intervention	   1/5	  (20%)	   5/5	  (100%)	   0	   0	  	   2/3	  	  (66.7%)	   13.89	   0.08	  Iron	  supplementation	  Intervention	  
4/19	  (21%)	   13/17	  (76.4%)	   3/19	  	  (15.8%)	   1/9	  (11.1%)	   5/6	  	  (16.7%)	   25.18	   0.00005	  
Combined	  key	  interventions	   46/109	  (42%)	   59/128	  (46%)	   53/115	  (46%)	   20/62	  (32%)	   22/65	  (33%)	   5.86	   0.21	  	  The	  Chi-­‐square	  test	  demonstrated	  no	  significant	  difference	  among	  the	  five	  sites	  when	  the	  key	  interventions	  were	  combined	  (p=0.21).	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Table	  9	  Summary	  of	  univariate	  analysis	  for	  combined	  key	  interventions	  	  Univariate	  analysis	  	  was	  performed	  and	  the	  enter	  method	  was	  used	  for	  selection	  of	  variables.	  	  The	  outcome	  variable	  was	  the	  combined	  overall	  protocol	  adherence	  (i.e.	  any	  correct	  clinical	  intervention	  based	  on	  the	  pre-­‐defined	  protocol;	  specifically,	  if	  any	  of	  the	  six	  clinical	  interventions	  was	  positive,	  then	  the	  combined	  variable	  will	  be	  positive).	  	  Each	  step	  was	  tested	  for	  goodness	  of	  fit	  with	  95%	  CI’s.	  	  Univariate	  analysis	  was	  performed	  for	  each	  predicator	  variable,	  including	  age,	  gender,	  weight,	  baseline	  creatinine,	  baseline	  systolic	  and	  diastolic	  blood	  pressures,	  baseline	  hemoglobin	  A1c,	  baseline	  urinary	  protein	  excretion	  rate,	  presence	  of	  angina	  and	  history	  of	  CABG.	  	  The	  significance	  level	  was	  0.1	  for	  retention	  in	  the	  multivariate	  model	  by	  default.	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  Variable	   P	  value	   Exp(B)	   95%	  C.I	  Age	   0.777	   1.005	   0.971-­‐1.039	  Gender	   0.630	   0.882	   0.529-­‐1.470	  Weight	   0.049	   1.015	   1.000-­‐1.030	  Baseline	  creatinine	   0.292	   1.005	   0.996-­‐1.015	  Baseline	  systolic	  blood	  pressure	   0.594	   1.004	   0.990-­‐1.018	  Baseline	  diastolic	  blood	  pressure	   0.300	   0.988	   0.965-­‐1.011	  Hemoglobin	  A1c	   0.712	   1.016	   0.933-­‐1.107	  Urinary	  protein	  excretion	  rate	   0.464	   1.273	   0.667-­‐2.427	  Presence	  of	  angina	   0.348	   3.429	   0.261-­‐45.026	  History	  of	  CABG	   0.395	   1.443	   0.620-­‐3.360	  	  “Weight”	  as	  a	  predictor	  in	  the	  univariate	  analysis	  was	  significantly	  associated	  with	  the	  positive	  likelihood	  of	  combined	  key	  interventions.	  	  Thus,	  “weight”	  was	  included	  in	  the	  regression	  analysis.	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Table	  10	  Regression	  analysis	  of	  combined	  key	  interventions	  	  The	  regressions	  analysis	  set	  the	  categorical	  independent	  variables	  as	  “interventional	  sites”	  and	  “weight”.	  	  The	  outcome	  variable	  was	  the	  combined	  overall	  protocol	  adherence	  (i.e.	  any	  correct	  clinical	  intervention	  based	  on	  the	  pre-­‐defined	  protocol)	  	  Site	   Site	  A	   Site	  B	   Site	  C	   Site	  D	   Site	  E	  P-­‐value	   0.038	   0.053	   0.824	   0.536	   0.465	  EXP	  (B)	  (95%	  C.I.)	   0.581	  	  (0.348	  –	  0.970)	  
1.656	  (0.994	  –	  2.758)	  
1.057	  (0.650	  –	  1.718)	  
1.221	  (0.648	  –	  2.301)	  
0.806	  (0.451	  –	  1.439)	  	  The	  logistic	  regression	  analysis	  demonstrated	  a	  potential	  small	  difference	  in	  Site	  A	  when	  compared	  to	  the	  overall	  effect:	  	  exp(B)	  0.581	  CI	  (0.348	  –	  0.970).	  	  The	  model	  evaluation	  	  was	  tested	  by	  the	  Omnibus	  test	  (0.037)	  ,	  Hosmer-­‐	  Lemeshow	  test	  (0.792)	  and	  -­‐2	  loglinear	  likelihood	  ratios	  (312.545)	  which	  suggested	  a	  good	  fit.	  	  The	  pseudo	  R2	  estimates,	  Cox-­‐Snell	  R2	  (0.049)	  and	  Nagelkerke	  R2	  (0.066)	  also	  supported	  the	  model.	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Table	  11	  Comparison	  of	  Nephrologist	  resource	  utilization	  in	  the	  five	  interventional	  sites	  	  The	  first	  row	  of	  this	  table	  describes	  the	  amount	  of	  time	  spent	  per	  week	  by	  each	  nephrologist	  at	  each	  site	  based	  on	  self-­‐reported	  time	  logs.	  	  The	  following	  row	  converted	  this	  time	  spent	  per	  week	  per	  study	  patient.	  	  The	  third	  row	  describes	  the	  time	  spent	  per	  study	  (104	  weeks	  or	  two	  years)	  per	  patient.	  	  The	  final	  row	  converted	  time	  spent	  to	  dollars	  spent	  based	  on	  the	  Ontario	  Medical	  Association	  wage	  scale.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   Site	  A	   Site	  B	   Site	  C	   Site	  D	   Site	  E	   F	   p-­‐value	  Minutes	  spent	  per	  week	   198.8	   58.1	   60	   212.5	   100	   5.588	   0.03	  Minutes	  spent	  per	  week	  per	  patient	   3.68	   0.985	   1.00	   7.33	   2.78	   	   	  Minutes	  spent	  per	  study	  (104	  weeks)/patient	  
382.72	   102.44	   104	   762.32	   289.12	   	   	  
Dollars/study/patient	  ($)	   877.38	   235	   238	   1,748	   663	   	   	  	  	  This	  ANOVA	  analysis	  identified	  significant	  differences	  in	  nephrologist	  resource	  use	  between	  the	  five	  sites.	  	  In	  particular,	  there	  is	  higher	  resource	  utilization	  by	  Sites	  A	  and	  D.	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Table	  12	  Comparison	  of	  the	  nursing	  resource	  utilization	  in	  the	  five	  interventional	  sites	  	  The	  first	  row	  describes	  the	  mean	  number	  of	  clinic	  visits	  per	  patient	  per	  year	  at	  each	  site.	  	  The	  next	  row	  describes	  the	  time	  spent	  per	  patient	  based	  on	  an	  average	  rate	  of	  69	  .3	  minutes	  per	  visit.	  	  The	  third	  row	  then	  describes	  the	  dollar	  spent	  per	  year	  based	  on	  an	  estimated	  hourly	  rate	  of	  $40.	  	  The	  final	  row	  summarizes	  the	  dollar	  spent	  per	  study	  (2	  years).	  	   Site	  A	   Site	  B	   Site	  C	   Site	  D	   Site	  E	   F	   p-­‐value	  Visit/year/patient	   4.06	   3.96	   3.98	   3.69	   3.72	   0.1055	   0.38	  Minutes/year	  (x69.3)	   281	   274	   276	   256	   258	   	   	  Dollars/year/patient	   187	   183	   184	   171	   172	   	   	  Dollars/study/patient	   374	   366	   368	   342	   344	   	   	  	  This	  ANOVA	  analysis	  demonstrated	  no	  difference	  in	  the	  resources	  used	  by	  the	  study	  nurses	  among	  the	  five	  sites.	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Discussion	  	  CANPREVENT	  was	  a	  randomized,	  unblinded,	  pilot	  clinical	  trial	  in	  patients	  with	  stage	  III	  and	  IV	  CKD.	  	  Its	  comparison	  of	  a	  nurse-­‐coordinated	  care	  model	  versus	  usual	  care	  by	  family	  physicians	  did	  not	  show	  any	  statistically	  significant	  difference	  in	  clinical	  endpoints	  or	  rate	  of	  decline	  in	  kidney	  function.	  	  However,	  the	  interventional	  group	  participants	  with	  suboptimal	  LDL	  levels	  or	  low	  iron	  saturation	  levels	  were	  more	  likely	  to	  receive	  treatment	  than	  their	  counterparts	  in	  the	  control	  group,	  even	  though	  the	  treatment	  effects	  were	  similar	  between	  two	  groups	  over	  time.	  	  This	  further	  sub-­‐analysis	  aimed	  to	  explore	  practice	  differences	  among	  the	  interventional	  sites	  regarding	  clinician	  adherence	  to	  established	  clinical	  protocols.	  	  Specifically,	  our	  hypothesis	  was	  that	  nursing	  background	  preparation/clinical	  expertise	  and	  relational	  continuity	  of	  care	  would	  affect	  overall	  clinical	  practice	  patterns.	  	  However,	  no	  major	  difference	  in	  the	  clinical	  practice	  pattern	  amongst	  the	  interventional	  sites	  was	  found.	  	  Overall,	  none	  of	  the	  interventional	  sites	  had	  consistently	  superior	  rates	  of	  clinical	  interventions.	  	  Nevertheless,	  there	  were	  specific	  differences	  with	  respect	  to	  various	  clinical	  interventions	  at	  each	  site.	  	  Specifically,	  at	  baseline,	  Site	  D	  had	  the	  highest	  proportion	  of	  diabetics	  and	  hypertensive	  patients	  (highest	  percentage	  of	  diastolic	  blood	  pressure	  above	  80	  mmHg).	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Amongst	  all	  the	  clinical	  interventions	  examined,	  Site	  C	  had	  the	  highest	  proportion	  of	  participants	  started	  on	  statins	  (76.2%,	  p=0.006).	  	  Site	  D	  had	  the	  highest	  percentage	  of	  diabetic	  clinic	  visits	  (57.1%,	  p=0.06),	  referral	  to	  a	  diabetic	  educator	  (71.4%,	  p=0.09),	  and	  dietitian	  referral	  (71.4%,	  p=0.09)	  amongst	  diabetics	  with	  suboptimal	  HbA1c;	  these	  were	  trends	  and	  not	  statistically	  significant,	  suggesting	  some	  degree	  of	  differential	  practice	  patterns	  at	  each	  site.	  	  Site	  A	  had	  a	  trend	  toward	  the	  highest	  number	  of	  hypertensive	  medication	  increases	  during	  the	  first	  three	  years	  of	  the	  study	  (45.4%,	  p=0.08)	  amongst	  hypertensive	  participants,	  	  while	  Site	  D	  had	  a	  trend	  to	  the	  highest	  proportion	  of	  overweight	  participants	  referred	  to	  a	  dietitian	  (54.4%,	  p=0.18)	  -­‐	  on	  both	  of	  these	  indicators,	  there	  were	  no	  statistically	  significant	  differences	  among	  centres	  .	  	  	  	  	  Site	  B	  had	  the	  highest	  proportion	  of	  new	  antiplatelet	  usage	  appropriately	  (100%,	  p=0.08),	  while	  also	  having	  the	  highest	  proportion	  of	  participants	  started	  on	  iron	  replacement	  therapy	  (76.4%,	  p=0.002).	  	  	  	  	  Based	  on	  these	  results,	  no	  clear	  definite	  association	  can	  be	  drawn	  between	  interventional	  sites,	  relational	  continuity	  of	  care	  and	  practice	  pattern.	  	  	  All	  the	  study	  sites	  other	  than	  Site	  E	  tended	  to	  emphasize	  certain	  aspects	  of	  the	  examined	  protocols.	  	  For	  example,	  Site	  A	  had	  the	  highest	  protocol	  adherence	  rate	  with	  hypertension	  control,	  Site	  B	  had	  the	  highest	  protocol	  adherence	  rate	  with	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antiplatelet	  and	  iron	  therapy,	  Site	  C	  had	  the	  highest	  protocol	  adherence	  rate	  with	  dyslipidemia	  control,	  while	  Site	  D	  had	  the	  highest	  protocol	  adherence	  rate	  with	  diabetic	  and	  weight	  management.	  	  It	  is	  unclear	  why	  this	  pattern	  occurred,	  but	  may	  certainly	  be	  a	  reflection	  of	  the	  site-­‐specific	  priorities	  in	  certain	  aspects	  of	  patient	  management,	  or	  it	  could	  be	  due	  to	  differential	  accessibility	  to	  services	  (dietitians,	  diabetic	  educators)	  across	  the	  sites.	  	  When	  the	  clinical	  interventions	  were	  combined,	  no	  clear	  association	  can	  be	  seen	  on	  the	  Chi-­‐square	  analysis	  between	  sites	  and	  overall	  protocol	  adherence	  (p=0.21).	  	  The	  univariate	  regression	  analysis	  demonstrated	  no	  significant	  p-­‐values	  for	  the	  predictors	  or	  age,	  gender,	  baseline	  creatinine,	  baseline	  blood	  pressure,	  baseline	  hemoglobin	  A1c	  levels,	  baseline	  urinary	  protein	  excretion	  rate,	  presence	  of	  angina	  and	  history	  of	  CABG.	  	  However,	  weight	  was	  significantly	  associated	  as	  a	  positive	  predictor	  of	  combined	  key	  intervention,	  and	  thus	  was	  included	  in	  the	  final	  regression	  model.	  	  The	  logistic	  regression	  did	  demonstrate	  a	  small	  potential	  difference	  with	  Site	  A,	  (sig.:	  0.038,	  exp(B)	  0.581,	  95%	  C.I.	  0.348	  –	  0.970).	  	  This	  site	  had	  diploma-­‐trained	  interventional	  nursing	  staff	  and	  no	  staff	  turnover	  demonstrated	  the	  least	  adherence	  to	  clinical	  protocols	  -­‐	  even	  though	  the	  overall	  clinical	  significance	  of	  the	  effect	  is	  small.	  	  	  	  Based	  on	  the	  results	  of	  the	  Chi-­‐square	  analysis	  and	  the	  small	  difference	  in	  the	  logistic	  regressions,	  we	  failed	  to	  definitively	  reject	  our	  null	  hypothesis.	  	  The	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discrepancy	  in	  the	  results	  between	  the	  Chi-­‐square	  test	  and	  the	  regression	  analysis	  could	  be	  due	  to	  the	  data	  sets	  used	  for	  each	  analysis.	  	  Specifically,	  the	  Chi-­‐square	  test	  was	  performed	  on	  the	  sum	  of	  all	  potential	  interventions,	  thus	  certain	  interventions	  were	  potentially	  counted	  multiple	  instances	  for	  a	  single	  participant,	  thereby	  making	  the	  variable	  less	  independent	  and	  thus	  introducing	  bias.	  On	  the	  other	  hand	  the	  regression	  analysis	  only	  counted	  one	  possible	  occurrence	  in	  each	  study	  participant,	  even	  though	  each	  participant	  could	  have	  required	  several	  interventions	  of	  which	  more	  than	  one	  might	  have	  been	  carried	  out.	  	  	  Site	  B	  was	  statistical	  significant	  in	  the	  regressions	  analysis	  and	  not	  in	  the	  Chi	  square	  analysis	  could	  be	  due	  to	  the	  possibility	  where	  particular	  participants	  at	  Site	  B	  had	  several	  interventions	  indicated,	  therefore	  would	  have	  appeared	  to	  have	  intervened	  positively	  even	  if	  only	  one	  of	  those	  interventions	  were	  carried	  out,	  ignoring	  the	  failures	  in	  the	  rest	  of	  the	  cases.	  	  The	  Chi	  square	  analysis	  would	  have	  captured	  those	  failures,	  and	  therefore	  found	  all	  sites	  to	  be	  equal.	  	  With	  respect	  to	  baseline	  patient	  factors	  and	  their	  influence	  on	  practice	  patterns,	  site	  D	  had	  the	  highest	  proportion	  of	  diabetic	  participants	  with	  suboptimal	  HbA1c,	  and	  it	  was	  demonstrated	  that	  site	  D	  also	  had	  the	  highest	  proportion	  of	  referrals	  to	  a	  diabetic	  educator.	  	  Beyond	  this	  observation,	  no	  clear	  association	  can	  be	  drawn	  with	  respect	  with	  participants’	  baseline	  clinical	  characteristics	  and	  practice	  patterns.	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There	  could	  be	  a	  number	  of	  explanations	  for	  these	  results.	  	  The	  overall	  trial	  sample	  size	  was	  limited	  and	  this	  analysis	  is	  further	  restricted	  to	  half	  of	  the	  participants	  of	  the	  CanPREVENT	  trial.	  	  The	  small	  sample	  size	  significantly	  reduces	  the	  power	  to	  detect	  even	  relatively	  large	  differences	  between	  the	  interventional	  sites.	  	  The	  power	  for	  our	  particular	  analysis	  could	  not	  be	  accurately	  calculated	  as	  we	  do	  not	  know	  the	  true	  magnitude	  of	  our	  proposed	  intervention.	  	  Nevertheless,	  the	  limited	  power	  in	  the	  our	  study	  was	  demonstrated	  by	  the	  regression	  analysis	  in	  table	  10,	  where	  the	  confidence	  intervals	  for	  Site	  B	  was	  1.140-­‐3.079,	  suggesting	  a	  potential	  three-­‐fold	  experimental	  effect	  at	  the	  upper	  end	  of	  the	  confidence	  interval,	  reflecting	  poor	  precision	  and	  thus	  too	  a	  small	  sample	  size	  to	  reject	  or	  accept	  our	  null	  hypothesis.	  	  	  This	  analysis	  was	  also	  performed	  on	  data	  collected	  from	  the	  interventional	  groups	  in	  each	  of	  the	  five	  sites.	  	  Due	  to	  the	  retrospective	  nature	  of	  the	  data	  collection,	  the	  intersite	  differences	  with	  respect	  to	  continuity	  and	  the	  background	  education	  of	  the	  staff	  were	  not	  all	  that	  clear	  and	  therefore	  it	  is	  difficult	  to	  unequivocally	  assess	  the	  impact	  of	  continuity	  and	  staff	  preparation	  on	  the	  outcomes	  of	  clinical	  protocol	  adherence.	  	  Furthermore,	  this	  study	  targeted	  patients	  with	  stage	  three	  and	  four	  chronic	  kidney	  disease	  in	  the	  community	  and	  recruited	  patients	  who	  were	  generally	  clinically	  well	  at	  baseline.	  	  The	  intent	  of	  the	  trial	  was	  to	  recruit	  a	  general	  population	  of	  those	  with	  CKD,	  rather	  than	  those	  already	  known	  to	  a	  nephrologist.	  	  For	  reasons	  of	  ethics,	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participants	  could	  only	  be	  recruited	  to	  the	  trial	  via	  their	  family	  doctors.	  	  This	  filter	  may	  have	  led	  to	  referral	  of	  low	  numbers	  of	  “at	  risk”	  patients,	  such	  as	  diabetic	  patients,	  patients	  with	  suboptimal	  LDL,	  HbA1c,	  as	  well	  as	  hypertensive	  patients.	  	  As	  well,	  most	  patients	  did	  not	  have	  significant	  established	  cardiovascular	  disease.	  	  Furthermore,	  most	  patients	  were	  already	  on	  treatment	  with	  an	  ACEI/ARB,	  not	  smoking,	  and	  had	  optimal	  blood	  pressure	  control	  and	  minimal	  proteinuria	  at	  baseline.	  	  The	  lack	  of	  clinical	  complexity	  and	  the	  perceived	  “wellness”	  of	  the	  interventional	  patients	  by	  the	  interventional	  research	  staff	  may	  have	  reduced	  staff	  enthusiasm	  for	  therapy	  intensification	  as	  per	  protocol.	  	  Another	  limitation	  of	  this	  study	  is	  that	  the	  participants’	  access	  to	  certain	  clinical	  services	  was	  variable	  across	  centres	  and	  this	  could	  not	  be	  accurately	  accounted	  for	  in	  our	  analysis.	  	  For	  instance,	  the	  access	  to	  a	  diabetic	  educator	  was	  variable	  across	  the	  five	  sites	  and	  this	  disparity	  would	  not	  have	  been	  measured	  or	  captured	  in	  our	  database.	  	  This	  could	  certainly	  have	  confounded	  the	  results	  of	  this	  analysis.	  	  Finally,	  despite	  having	  an	  established	  clinical	  protocol	  and	  dedicated	  interventional	  research	  staff	  executing	  the	  protocols,	  participants’	  adherence	  to	  therapy	  may	  have	  biased	  the	  final	  result.	  	  Non-­‐adherence	  in	  Stage	  V	  CKD	  (dialysis)	  patients	  to	  prescribed	  oral	  medications	  was	  described	  in	  a	  systematic	  review,	  where	  the	  median	  non-­‐adherence	  rate	  is	  50%	  (75).	  	  Therefore,	  if	  a	  particular	  intervention	  or	  medication	  was	  prescribed	  by	  study	  staff	  but	  not	  ultimately	  carried	  through	  by	  the	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participant,	  then	  it	  would	  appear	  in	  the	  database	  that	  the	  intervention	  or	  medication	  was	  never	  prescribed.	  	  This	  could	  happen	  because	  the	  database	  only	  included	  the	  clinical	  interventions	  each	  participant	  received	  at	  each	  visit	  although	  the	  prescription	  pattern	  by	  research	  staff	  was	  not	  actually	  recorded.	  	  For	  instance,	  attendance	  at	  a	  diabetic	  clinic	  rather	  than	  the	  referral	  by	  staff	  to	  that	  clinic	  would	  be	  recorded,	  as	  well	  as	  the	  drugs	  the	  patient	  said	  they	  were	  taking	  at	  each	  visit	  rather	  than	  what	  had	  been	  prescribed	  for	  them	  at	  an	  earlier	  time.	  	  Since	  this	  particular	  level	  of	  patient	  adherence	  was	  not	  captured	  in	  the	  study	  database,	  patient	  non-­‐adherence	  could	  have	  been	  interpreted	  as	  prescriber	  non-­‐adherence	  even	  though	  the	  intervention	  might	  have	  been	  prescribed.	  	  This	  is	  a	  limitation	  of	  the	  study	  data	  and	  patient	  non-­‐compliance	  across	  each	  site	  could	  have	  significantly	  contributed	  to	  the	  relatively	  neutral	  result	  of	  this	  analysis.	  	  	  	  In	  patients	  with	  chronic	  diseases,	  a	  meta-­‐analysis	  previously	  reported	  that	  provider	  education	  (materials	  or	  instruction	  given	  to	  healthcare	  providers	  regarding	  appropriate	  care	  for	  patients	  with	  the	  condition	  targeted	  by	  the	  program),	  giving	  feedback	  to	  healthcare	  providers,	  and	  periodic	  reminders	  prompting	  specific	  patient	  care	  tasks	  were	  associated	  with	  improvements	  in	  provider	  adherence	  to	  guidelines	  in	  disease	  management	  programs.(76)	  Further	  research	  in	  CKD	  management	  could	  address	  all	  or	  some	  of	  these	  variables	  in	  order	  to	  elucidate	  their	  relative	  effects	  on	  guideline	  adherence.	  	  On	  the	  other	  hand,	  patient	  behaviour	  and	  adherence	  is	  more	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difficult	  to	  accurately	  measure	  and	  quantify	  and	  may	  improve	  with	  patient	  education	  and	  incentives.(76)	  	  The	  researcher	  originally	  hypothesized	  an	  association	  between	  nursing	  expertise/background	  education	  	  and	  protocol	  adherence.	  	  However,	  nursing	  expertise	  proved	  to	  be	  a	  challenging	  variable	  to	  quantify	  because	  of	  the	  turnover	  of	  staff	  and	  the	  retrospective	  nature	  of	  the	  analysis.	  	  The	  inability	  to	  ascertain	  and	  quantify	  nursing	  expertise	  is	  a	  limitation	  of	  this	  study.	  	  This	  type	  of	  research	  is	  inherently	  difficult	  to	  conduct	  as	  it	  involves	  multiple	  complex	  interventions	  and	  many	  different	  care-­‐provider	  characteristics.	  	  For	  instance,	  the	  care	  provider’s	  educational	  preparation	  could	  influence	  patient-­‐related	  outcomes.	  	  The	  literature	  suggests	  that	  a	  master’s	  level	  nursing	  education	  can	  result	  in	  improved	  patient	  outcomes,	  while	  being	  specifically	  trained	  in	  a	  medical	  specialty	  could	  enhance	  clinical	  decision	  making.(77)	  Provider	  experience,	  especially	  in	  a	  specialty	  area	  (i.e.	  nurse	  subspecialty	  certification),	  could	  also	  impact	  on	  the	  overall	  patient	  care	  and	  outcomes	  although	  any	  conclusion	  with	  respect	  to	  true	  association	  is	  limited	  by	  the	  paucity	  of	  the	  current	  evidence.	  	  These	  areas	  need	  to	  be	  further	  explored	  in	  future	  research.	  	  Regarding	  the	  resource	  utilization	  findings	  of	  the	  study,	  this	  particular	  analysis	  demonstrated	  that	  there	  was	  higher	  nephrologist	  resource	  utilization	  at	  Sites	  A	  and	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D,	  although	  these	  data	  may	  be	  biased	  as	  they	  were	  largely	  based	  on	  retrospective	  recall	  and	  self-­‐reporting	  by	  each	  site	  nephrologist.	  	  Nevertheless,	  a	  potential	  explanation	  for	  this	  statistically	  significant	  higher	  nephrologist	  resource	  utilization	  could	  be	  due	  to	  the	  absence	  of	  a	  clinical	  nurse	  specialist.	  	  The	  presence	  of	  the	  clinical	  nurse	  specialist	  at	  site	  C	  could	  have	  resulted	  in	  reduced	  nephrologist	  cost	  because	  a	  clinical	  nurse	  specialist	  could	  manage	  a	  greater	  number	  of	  issues	  normally	  managed	  by	  a	  nephrologist.	  	  	  On	  the	  other	  hand,	  the	  nursing	  resource	  (time)	  utilization	  was	  similar	  between	  the	  sites	  despite	  the	  difference	  in	  nursing	  expertise	  and	  staffing	  continuity.	  	  This	  confirmed	  the	  notion	  that	  nursing	  clinic	  visits	  and	  hence	  resources	  utilization	  were	  largely	  driven	  by	  the	  pre-­‐defined	  protocol	  for	  the	  trial	  with	  little	  deviation	  in	  the	  form	  of	  extra	  clinic	  visits.	  	  Another	  limitation	  to	  the	  nephrologist	  resource	  utilization	  analysis	  was	  that	  the	  nephrologist	  costs	  (time)	  were	  heavily	  influenced	  by	  the	  personal	  practice	  patterns	  of	  each	  study	  nephrologist	  whose	  personal	  commitment	  and	  engagement	  in	  the	  trial	  or	  in	  patient	  care	  may	  not	  have	  been	  heavily	  influenced	  by	  the	  nursing	  practice	  pattern	  and	  expertise.	  	  There	  are	  several	  limitations	  to	  this	  research:	  	  Firstly,	  this	  was	  a	  post-­‐hoc	  analysis	  of	  the	  original	  CanPREVENT	  clinical	  trial	  data,	  which	  might	  not	  have	  generated	  enough	  power	  to	  detect	  any	  statistical	  difference	  between	  the	  interventional	  sites.	  	  Secondly,	  the	  relational	  continuity	  of	  care	  within	  the	  interventional	  sites	  was	  determined	  retrospectively	  which	  limited	  the	  robustness	  of	  the	  results.	  	  The	  nature	  of	  the	  relationship	  between	  the	  nurses	  and	  patients,	  between	  physicians	  and	  patients,	  and	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physicians	  and	  nurses	  was	  not	  measured.	  It	  may	  be	  that	  the	  specific	  nature	  of	  those	  relationships	  has	  an	  impact	  on	  patient	  care	  and	  outcomes.	  This	  research	  involves	  many	  complex	  interventions	  and	  many	  different	  patient	  characteristics	  and	  protocol	  adherence	  patterns,	  making	  the	  identification	  of	  a	  single	  positive	  effect	  difficult.	  	  It	  would	  be	  more	  desirable	  from	  an	  evidence-­‐based	  point	  of	  view	  to	  have	  separate	  treatment	  groups	  defined	  a	  priori	  to	  test	  the	  hypothesis	  of	  an	  association	  between	  relational	  continuity	  of	  care	  or	  nursing	  preparation	  level/expertise	  and	  clinical	  outcomes.	  	  	  	  If	  the	  present	  research	  question	  had	  been	  identified	  a	  priori	  and	  the	  CanPREVENT	  trial	  were	  to	  be	  redesigned,	  there	  would	  be	  separate	  treatment	  arms	  with	  nurses	  with	  varying	  degrees	  of	  expertise	  and	  educational	  background,	  as	  well	  as	  introducing	  a	  variable	  of	  different	  levels	  of	  relational	  continuity	  (e.g.	  a	  treatment	  arm	  with	  one	  provider	  vs.	  a	  treatment	  arm	  with	  two	  or	  three	  providers).	  	  	  For	  example,	  to	  test	  the	  hypothesis	  that	  different	  levels	  of	  nursing	  education	  and	  training	  can	  affect	  patient	  outcomes;	  one	  could	  have	  a	  predefined	  group	  of	  interventional	  nurses	  with	  and	  without	  nephrology	  nursing	  subspecialty	  preparation.	  	  Within	  each	  of	  these	  two	  groups,	  one	  could	  further	  define	  groups	  of	  registered	  nurses	  with	  diploma,	  baccalaureate,	  and/or	  a	  master’s	  preparation.	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Different	  levels	  of	  relational	  continuity	  can	  be	  achieved	  by	  predefined	  groups	  where	  site	  A	  would	  have	  one	  nurse	  as	  interventional	  nurse	  for	  the	  duration	  of	  the	  study,	  and	  site	  B	  would	  have	  one	  nurse	  per	  year	  for	  the	  duration	  of	  the	  study.	  	  To	  incorporate	  both	  independent	  variables	  of	  nursing	  expertise	  and	  relational	  continuity	  of	  care	  into	  the	  study	  design,	  one	  could	  generate	  a	  2	  X	  3	  factorial	  design	  template.	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Conclusion	  It	  was	  not	  possible	  to	  detect	  a	  significant	  difference	  between	  the	  relational	  continuity	  or	  nursing	  background	  educational/clinical	  expertise	  in	  the	  management	  of	  the	  care	  of	  stage	  III	  and	  IV	  CKD	  patients	  and	  their	  surrogate	  clinical	  outcomes.	  	  	  	  However,	  this	  study	  design	  was	  retrospective	  in	  nature	  and	  a	  larger	  participant	  sample	  with	  increased	  power	  may	  provide	  different	  results.	  	  A	  more	  definitive	  randomized	  clinical	  trial	  with	  a	  larger	  sample	  size	  (sites	  and	  patients)	  and	  longer	  follow-­‐up,	  thereby	  increasing	  the	  power,	  is	  required	  to	  examine	  this	  hypothesis.	  	  	  The	  management	  of	  patients	  with	  CKD	  is	  becoming	  more	  complex	  as	  more	  interventions	  are	  becoming	  available	  to	  treat	  its	  complications	  and	  co-­‐morbid	  conditions.	  	  	  Research	  is	  also	  elucidating	  interventions	  to	  prevent	  the	  risk	  of	  progression	  to	  end	  stage	  renal	  disease.	  	  The	  current	  model	  of	  a	  single	  nephrologist-­‐delivered	  CKD	  care	  is	  not	  optimal	  and	  likely	  not	  sustainable	  in	  the	  future.	  	  More	  studies	  are	  needed	  to	  examine	  the	  most	  effective	  and	  efficient	  means	  of	  delivering	  care	  to	  CKD	  patients.
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